











This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
• This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
• A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
• This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
• The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
• When referring to this work, full bibliographic details including the author, title, 





cardiovascular and renal risk 
factors using antagonists of the 






Iain McGregor MacIntyre 
Presented for the degree of Doctor of Philosophy 
 
 




























































































































































I declare that all the work presented in this thesis is my own except where stated 
below, and it has been entirely composed by myself. 
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and Miss D Kerr. 
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and Miss D Kerr. 
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laboratory staff of the Clinical Pharmacology Unit (Mr NR Johnston, Miss E Cole, 
Miss L Bruce). I and others, as outlined above, undertook all immediate processing 
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24 hour urinary protein and creatinine (Chapter 6): These were processed in the 
main hospital laboratory. 
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Chapter 3: I analysed the data for study 1 with the help of Dr J Goddard 
Chapter 4: I analysed the data for study 2 with the help of Dr J Goddard 
Chapter 5: I analysed the data for study 3 with the help of Dr J Goddard 
Chapter 6: Dr N Dhaun, Dr J Goddard and I analysed the date for study 4 
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Chronic kidney disease (CKD) is an important independent risk factor in the 
development of cardiovascular disease (CVD). Indeed, patients with CKD are far 
more likely to die from CVD than reach end stage renal disease. Conventional 
cardiovascular risk factors and co-morbidity contribute to this increased risk of CVD. 
However, emerging evidence suggests other novel factors including inflammation, 
oxidative stress, and a shift in the balance of the vasodilator nitric oxide and 
vasoconstrictor endothelin system, are also important contributors.  Despite 
increasing evidence that the endothelin system plays an important role in the 
development of CKD and CVD, there has been little research examining possible 
therapeutic benefits of its modification in patients with CKD. The overall aims of the 
work presented within this thesis were to examine CVD risk in patients with renal 
impairment and then to see what impact chronic inhibition of the endothelin system 
would have on risk factors for CVD and CKD progression. 
 
In the first two studies I examined markers of arterial stiffness (AS) and endothelial 
function in a cohort of patients with immune-mediated renal disease. I was able to 
show in the acute setting that improvement in renal function following treatment for 
these conditions leads to significant improvements in AS. Interestingly, in patients 
who were in remission from their renal disease, only classical cardiovascular risk 
factors appear to be linked to AS. In the next study I was able to prove that 
sitaxsentan, a selective oral ETA antagonist, did not cause functional blockade of the 
ETB receptor in man. This was the first study of its kind to confirm that a “selective” 
endothelin antagonist truly is selective in vivo: a finding that will allow more 
accurate mechanistic investigation of the ET system.  In the final studies, I showed 
that in subjects with stable non-diabetic proteinuric CKD, chronic selective ETA 
receptor antagonism reduces blood pressure and AS, and that these systemic benefits 
are associated with an increase in renal blood flow and reduction in proteinuria. The 
reduction in proteinuria is most likely haemodynamic and linked to a fall in GFR and 
filtration fraction, similar to what is seen with ACE inhibitors. Importantly, these 
benefits were seen in patients already taking maximally tolerated renin-angiotensin-
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aldosterone system blockade, suggesting that chronic endothelin antagonism could 
be an important future therapy in the management of CKD.  
 
In summary, I have shown that renal impairment can directly affect markers of 
arterial function and by inference increase the risk of CVD. Chronic antagonism of 
the endothelin system with ETA receptor blockers would appear to improve many of 
these biomarkers, including reductions in BP, AS and proteinuria. There were no 
adverse effects reported in these studies, suggesting that selective ETA antagonism 
may be safe enough for clinical development in CKD patients.  Further larger clinical 
trials are warranted.  
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1.1 Chronic Kidney Disease 
Chronic kidney disease (CKD) is a long-term condition caused by damage to the 
kidneys and is increasingly being recognised as a major public health problem. It is 
categorised, according to levels of renal function, by internationally accepted 
definitions requiring structural or functional abnormalities of the kidneys which 
persist for greater than 3 months (Table 1.1)1, 2. It is common, with an average 
prevalence of approximately 11% within the populations of the United States of 
America (USA) and Western Europe3. Within the UK, prevalence of stage 3-5 CKD 
is 6%, with this rising to 13-14% when including stages 1 & 24. Furthermore, as 
CKD is seen more frequently in the elderly it is likely that its prevalence will 
continue to increase as the population ages5.  
 
Table 1.1 Stages of chronic kidney disease2 
Stage eGFR (ml/min/1.73 m2) Description 
1 90 or more Normal or increased eGFR, with other 
evidence of kidney damage 
2 60 – 89 Slight decrease in eGFR, with other evidence 
of kidney damage 
3A 45 – 59 Moderate decrease in eGFR, with or without 
other evidence of kidney damage 
3B 30 – 44 Moderate decrease in eGFR, with or without 
evidence of kidney damage 
4 15 – 29 Severe decrease in eGFR, with or without 
evidence of kidney damage 
5 < 15 Established renal failure 
 
CKD represents a major clinical and financial burden for two main reasons. Firstly, 
despite current best treatments, many patients with CKD continue to have declining 
function, with a small but significant number of patients progressing to end-stage 
renal disease (ESRD) requiring dialysis or transplantation. Estimates suggest the 
current world dialysis population is greater than 2 million patients with a treatment 
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cost of over $100 billion per annum6. Within NHS England, annual spending on 
CKD was estimated at £445 million in 2002. However, by 2010 this had more than 
trebled to £1.64 billion7.  Moreover, using data from the Renal Registry, the number 
of patients receiving renal replacement therapy in the UK has increased steadily over 
the last 15 years (~4% a year) and currently stands at 53,207 adult patients (Figure 
1.1)8.  Secondly it is now well recognised that CKD is strongly associated with 
cardiovascular disease9. Indeed, dialysis patients have mortality rates 10-100 times 
greater in than the general population10, 11. Patients with less severe kidney 
dysfunction (chronic CKD stages 3-5) are also at increased risk of cardiovascular 
death12, 13. Indeed those with stages 4-5 CKD are up to 10 times more likely to die 
from CVD than to reach ESRD14. While many patients with CKD have traditional 
risk factors for CVD such as diabetes mellitus, smoking and hypertension, part of the 
increased risk is attributable to CKD itself or more novel markers associated with 
CKD 15, 16. Such findings have led the US National Kidney Foundation Task Force 
on CVD in Chronic Renal Disease to recognise that patients with CKD should be 
considered in the highest risk group for subsequent cardiovascular events17.  
 
Figure 1.1 Growth in end-stage CKD 1997-2011  
(UK Renal Registry 15th Annual Report8) 
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It is clear from these figures that patients with CKD represent a large group within 
the population who suffer high morbidity and mortality. There is, therefore, a need to 
further investigate the cardiovascular burden associated with CKD and study 
possible treatment strategies that will not only slow renal decline, but also reduce 
cardiovascular risk in these patients.  
 
1.2 The link between CKD and CVD 
Evidence for the relationship between CKD and CVD was first recognised in the 
1970s within the dialysis population18. In the UK approximately 20% of patients 
with ESRD will die from a cardiovascular (CV) cause19. Studies within the general 
population have shown that the relationship between CKD and CVD also extends to 
those with only mild to moderate renal impairment. The Cardiovascular Health Study 
was a prospective population-based study of 5,808 subjects aged ≥65 yr, with an 
average follow-up of 7.3 yr. Renal insufficiency, defined as a serum creatinine value 
>130mol/L in men and 115mol/L in women, was present in 11.2% of 
participants20. Subjects with renal insufficiency were more likely to develop 
cardiovascular disease, congestive heart failure, and symptomatic peripheral vascular 
disease, as well as to die: these associations were not eliminated by adjusting for 
traditional cardiovascular risk factors. More recently Go et al.12 analysed the 
database of a large healthcare  provider in Northern California, stratifying over a 
million subjects according to estimated glomerular filtration (eGFR) as calculated by 
the Modification of Diet in Renal Disease (MDRD) formula21. Mean follow up was 
2.8 years. After adjustment for age, sex, race, coexisting illness and socioeconomic 
status, a stepwise increase in death, CV events and hospitalisation was seen with 
decreasing eGFR. This large study, along with others, clearly demonstrates an 
independent and inverse graded relationship between glomerular filtration and CVD. 
 
1.2.1 Proteinuria 
CKD may not only be identified by impaired glomerular filtration but also by the 
presence of proteinuria22.  Indeed proteinuria often precedes reductions in eGFR and 
is a powerful predictor of renal disease progression23. It is likely that proteinuria also 
has a direct deleterious effect on renal tubular cells, causing tubulointerstitial 
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inflammation with subsequent fibrosis and thereby contributing to progressive renal 
failure 24-26. Furthermore, just like reductions in eGFR, proteinuria has been shown to 
be a strong independent determinant of CVD in both the diabetic and non-diabetic 
population. The association between proteinuria and CVD was first noted in those 
patients with overt macroalbuminuria (albumin:creatinine ratio [ACR] 
>30mg/mmol) and was found to be independent of traditional CV risk factors27, 28. 
More recently it has become increasingly recognised that the risk of CVD is 
increased with microalbuminuria and even within the currently defined normal levels 
of albuminuria (ACR <3mg/mmol)29-31. For example, Hillege et al. followed 40,000 
members of the general public from the city of Groningen29. Subjects were asked to 
fill in a medical questionnaire and provide an early morning urine specimen and 
were then followed up for an average of almost 3 years. After adjusting for known 
CVD risk factors, the investigators found that a doubling of the urinary albumin 
excretion rate, even when still within the ‘normal’ range was associated with a 
relative risk of 1.29 (95% confidence interval 1.18 to 1.40) for CV mortality. 
Furthermore, microalbuminuria outranked the predictive power of other classic CV 
risk factors.  
 
Analysis of the urinary data from the Heart Outcomes Prevention Evaluation 
(HOPE) study also appears to support the view that microalbuminuria is an important 
independent risk factor for CVD. In short, the HOPE study recruited 9297 high-risk 
patients aged ≥55 years of age who had evidence of vascular disease or diabetes plus 
one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, 
low high-density lipoprotein cholesterol levels, cigarette smoking, or documented 
microalbuminuria), and randomly assigned them to receive ramipril (10 mg once per 
day) or matching placebo for a mean of five years32. Post hoc analysis of the urinary 
data revealed that in the overall study population, a baseline ACR of >2.0 mg/mmol 
increased the adjusted relative risk of CV events to 1.8333. Further analysis of the 
HOPE data suggests that albuminuria is a continuous risk factor for CV events with 
the adjusted hazard of major CV events increasing by 5.9% for every 0.4 mg/mmol 
increase in ACR30. 
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It is well established that proteinuria is associated with renal disease progression34, 35 
and reduction of proteinuria appears to reduce the rate of GFR decline23, 36-39. 
Importantly, there is also evidence that proteinuria is a modifiable risk factor for 
CVD. The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) 
study involved around 8200 subjects with hypertension who were randomised to 
receive losartan or atenolol40. Baseline albuminuria was measured in all patients and 
as expected was found to be a powerful predictor of CVD mortality. Despite losartan 
and atenolol achieving similar blood pressure reductions (30.2/16.6 mmHg vs. 
29.1/16.8 mmHg), patients in the losartan group had significantly greater reductions 
in albuminuria and CVD outcomes suggesting that reductions in urine ACR over 
time translate into reduced cardiovascular risk. Similarly, in the Reduction in 
Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II 
Antagonist Losartan (RENAAL) study there was an 18% reduction in cardiovascular 
risk for every 50% reduction in albuminuria41. All of this suggests that as well as 
being a marker of renal damage, proteinuria is a direct target for the treatment of 
CVD in patients with CKD. 
 
1.2.2 Hypertension 
Hypertension, defined as a systolic BP (SBP) of 140 mmHg or a diastolic BP 
(DBP) 90 mmHg, is accepted as one of the strongest prognostic markers for the 
development of cardiovascular disease and death42, 43 with BP values bearing a 
continuous linear relation with the incidence of cardiac events. Importantly, a 5 
mmHg reduction in a given SBP results in a 22% reduction in cardiovascular 
events44. 
 
Hypertension can be either a consequence or cause of CKD and is associated with 
adverse outcomes including worsening renal function and CVD. Its prevalence 
increases as GFR falls, hypertension being found in around 20% of patients with 
stage 1 CKD compared to more that 80% of patients with stage 4 CKD45.  Moreover, 
treatment resistant hypertension, defined as a BP above target despite adherence to at 
least 3 different antihypertensive agents, including a diuretic, is 2.5-3 times more 
common in patients with CKD compared to those without46.  
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Progression of renal damage secondary to hypertension can be split into 3 categories: 
the systemic BP load, the degree to which such a load is transmitted to the renal 
vascular bed and the local tissue susceptibility to any given degree of barotrauma47. 
Under normal conditions, renal blood flow (RBF) varies little within a broad range of 
BPs. As BP increases vasoconstriction of the afferent glomerular arteriole occurs 
maintaining RBF and glomerular pressures. However, this autoregulatory process 
can be blunted as a result of renal disease or diabetes, leading to increased pressure 
load to the kidney, resulting in barotrauma to the glomerulus and, over time, 
glomerulosclerosis results. Furthermore, damage to the glomerular capillaries and 
mesangium also promotes increased proteinuria, which in turn promotes further 
glomerular and tubulointerstitial injury. Importantly, renal impairment can also drive 
systemic hypertension through numerous mechanisms including the expansion of the 
extracellular volume via sodium retention, increased sympathetic activity, an 
inappropriately increased activation of the renin-angiotensin-aldosterone system 
(RAAS), impaired endothelial function and high parathyroid hormone levels48. As a 
consequence a vicious cycle of hypertension and renal damage can result.  
 
Numerous studies have confirmed that BP is an important independent risk factor for 
ESRD. In the Kaiser Permanente cohort, a graded association between BP and risk of 
ESRD among subjects, without clinical evidence of CKD at baseline, was shown 
over a 20-year period. This held true even at BPs that would be described as normal 
(systolic of 120-129 mmHg) and suggests that non-malignant hypertension is an 
independent risk factor for CKD progression49. Furthermore, the RENAAL study, 
which followed patients with diabetic nephropathy for an average of 3.4 years, found 
that for every 10 mmHg rise in baseline SBP there was a 7% increase the risk of 
death or ESRD50. Importantly, reductions in BP have also been shown to reduce the 
rate of renal functional decline. In one meta-analysis of 11 studies involving 1860 
patients with CKD, results showed that the lowest risk for kidney disease progression 
seemed to be at a SBP of 110 to 129 mmHg and urine protein excretion less than 2.0 
g/d. Interestingly, at levels of urine protein excretion less than 1.0 g/d, there was little 
relationship between risk for kidney disease progression and current SBP from 110 
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to 159 mmHg23. Based on these results and those of other studies, current guidelines 
suggest aggressive management of BP in patients with proteinuric CKD, aiming for 
130 mmHg systolic and 80 mmHg diastolic51.  
 
1.2.3 Endothelial dysfunction 
The endothelium is a single layer of cells that line the entirety of the vascular system.  
It plays a pivotal role in a number of vascular functions including vascular tone, 
thrombosis, inflammation and permiability52. Endothelial dysfunction (ED), 
characterised by impaired endothelium-dependent vasodilatation, enhanced 
endothelium-dependent vasoconstriction and a proinflammatory and prothrombotic 
state52, is recognised as one of the initial mechanisms in the development of 
atherosclerosis and is associated with increased risk of subsequent CV events53. Its 
development is linked to hypertension, reduced nitric oxide (NO) generation, 
oxidative stress and inflammation52.  
 
ED has been demonstrated in patients with CKD when compared to controls, and 
undoubtedly plays an important role in the development of CVD in this group52, 54, 55.  
Interestingly, there appears to be an association between ED and microalbuminuria 
that may explain, at least in part, why microalbuminuria strongly predicts CV 
events56. Furthermore, animal models of CKD suggest that ED promotes further 
reductions in renal function and promotes proteinuria57, 58. This in turn, may further 
exacerbate ED and promote further atherogenesis, in effect creating a vicious cycle. 
The Hoorn Study has show that even mild impairment of renal impairment is 
independently associated with ED and this in turn with associated with increased 
cardiovascular mortality55. In more severe renal disease reduced bioavailability of 
NO appears to be an important factor59, 60, in large part due to increased oxidative 
stress and high concentrations of plasma asymmetric dimethylarginine (ADMA)59, 61, 
62. 
 
ADMA, an endogenous competitive inhibitor of NO synthase, is formed during the 
catabolism of proteins containing methylated arginine residues62. Within the 
cardiovascular system it is synthesised within the heart, endothelium and smooth 
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muscle cells. Exogenous ADMA inhibits NO generation in vitro and in healthy 
humans reduces forearm blood flow, cardiac output and renal blood flow, as well as, 
increasing BP, systemic vascular resistance and sodium retention62, 63. Plasma 
concentrations of ADMA are increased in association with ED, particularly in 
patients with renal disease62, 64. The increased concentrations of ADMA in renal 
impairment may result from both increased activity of protein arginine 
methyltransferase and reduced metabolism of ADMA via dimethylarginine 
dimethylaminohydrolase  (DDHA)65. As well as being a marker for ED, ADMA 
levels strongly correlate to atherosclerosis and cardiovascular mortality66-68. With 
regard to renal disease, plasma ADMA is inversely related to GFR69 and is an 
independent risk factor for progression to ESRD and mortality65, 70.  
1.2.4 Arterial Stiffness 
One of the major functions of the large elastic arteries of the body (most notably the 
aorta) is to convert intermittent pulsatile blood flow to a more steady flow. This is 
achieved by the artery expanding during systole and then recoiling during diastole, 
promoting forward flow.  AS is the reduced capability of an artery to expand and 
contract in response to pressure changes and leads to increasing systolic and lower 
diastolic pressures (See Figure 1.2)71. Increasing AS is a consequence of arterial 
damage and develops from a complex interaction between stable and dynamic 
changes involving structural and function of the vessel wall (Fig 1.3)72.  
 
AS leads to increased SBP, which in turn, leads to increased left ventricular work-
load and subsequent gradual development of left ventricular hypertrophy (which is 
associated with a 2-5 fold increase in cardiovascular events73). There is also an 
associated fall in diastolic pressures, potentially impairing coronary blood flow. 
Pulse pressure is increased and may have direct effects on end organs including on 
the kidney where it causes afferent arteriolar constriction and subsequent reduction 
in GFR 74. AS is also linked to ED75. Evidence from animal76, 77 and human78, 79 









Figure 1.3 Factors involved in arterial stiffness. 
Modified from Zieman et al.72
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Aortic stiffness has predictive value for all-cause and cardiovascular mortality, as 
well as total cardiovascular events. A 2010 meta-analysis of 17 longitudinal studies 
that evaluated aortic pulse wave velocity (PWV; a marker of aortic stiffness) found 
that an increase in aortic PWV by 1 m/s corresponded to an age-, sex-, and risk 
factor–adjusted risk increase of 14%, 15%, and 15% in total CV events, CV 
mortality, and all-cause mortality, respectively, implying that AS is a strong 
predictor of future CV events and all-cause mortality80. The additional value of AS 
above and beyond traditional cardiovascular risk factors has been quantified by 3 
separate studies81-83. Boutouyrie et al. assessed the predictive value of AS on 
coronary heart disease in 1045 patients with essential hypertension and without 
known clinical cardiovascular disease. In univariate analysis, the relative risk of 
follow-up coronary event or any cardiovascular event increased with increasing level 
of PWV; for 1 SD (3.5 m/s) relative risks were 1.42 (1.10 to 1.82; P<0.01) and 1.41 
(1.17 to 1.70; P<0.001), respectively. With multivariate analysis, PWV remained 
significantly associated with the occurrence of coronary event after adjustment for 
Framingham scoring81. This improved ability of aortic stiffness to predict CV 
mortality was confirmed by Mattace-Raso et al.82 in a study of 2835 subjects 
participating in the third examination phase of the Rotterdam Study and by Sehestedt 
et al. in middle-aged subjects from a general population83. These studies suggest that 
aortic stiffness in many ways could be considered as a surrogate end-point for CV 
events84. 
 
Studies have demonstrated that patients with renal dysfunction have stiffer arteries 
than healthy subjects and this stiffness increases with declining GFR85-88. Wang et al. 
85 demonstrated a step wise increase in PWV with increasing CKD stage. Further 
work in a group of 113 patients with CKD but no history of cardiovascular disease or 
diabetes confirmed a step-wise increase in AS as renal function declines88 (Fig 1.4). 
This suggests that arterial damage occurs long before ESRD is reached and would be 
in keeping with data showing that patients with non-dialysis-requiring CKD are more 






Figure 1.4 Aortic stiffness vs. GFR. 
Scatter plots show a significant negative correlation between carotid–femoral 
pulse wave velocity (CF-PWV) and eGFR. Box plots show CF-PWV by CKD 
stage including a control group. *Stage 5 vs. control, p < 0.01. Figure taken 






















AS has been shown to be an independent predictor of all-cause and CVD mortality in 
patients with ESRD89, 90. It has also been shown by Guerin et al.91 that reduction in 
CVD mortality is only achieved when BP reduction and control is associated with a 
reduction in AS in ESRD patients. Those patients with adequate BP control but high 
PWV do not see as great a reduction in mortality. It would therefore appear that AS 
as well as being a marker of CVD is also a valuable target for early treatment. 
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1.2.5 Inflammation and oxidative stress 
Chronic inflammation contributes to the development of atherosclerosis92. As CVD 
burden increases, established markers of inflammation such as high sensitivity C-
reactive protein (hsCRP), the cytokines interleukin-6 (IL-6) and tumor necrosis 
factor  (TNF), and soluble intercellular adhesion molecule (sICAM-1) increase. 
This relationship holds true even after adjustment for traditional CVD risk factors93. 
 
Systemic low-grade inflammation has been linked to impaired endothelial function94, 
95. C-reactive protein (CRP) is an acute-phase protein, the main physiological role of 
which is to activate the complement system via the C1Q complex and clinically is 
widely used as a marker of inflammation. Fichtlscherer et al.94 demonstrated an 
inverse correlation between CRP and forearm blood flow responses to acetylcholine 
in males with documented CVD. Further study has shown that CRP is an 
independent determinant of endothelium-dependent vascular function, even in 
apparently healthy subjects, and that there is a relationship between low-grade 
chronic inflammation and basal endothelial NO synthesis 95. CRP has also been 
shown to correlate to AS as measured by PWV96. Interestingly, a consistently 
elevated CRP was found to have a far greater correlation with AS that many 
traditional CVD risk factors in a general population of middle-aged men96. Even 
acute low-level inflammation in otherwise healthy individuals causes a rise in PWV. 
Vlachopoulos et al.97 showed that vaccination (Salmonella typhi) produced a 
significant increase in PWV (at 8 hours by 0.43 m/s). There were associated 
significant increases in inflammatory markers (hsCRP and hsIL-6).  
 
Irrespective of the cause of renal disease there is firm evidence that a chronic pro-
inflammatory state exists in patients with CKD98. While associated disease such as 
hypertension, diabetes and atherosclerosis may contribute, it is also likely that 
hypoalbuminaemia/malnutrition99, dyslipidaemia100, advanced glycation end 
products101, oxidative stress102 and upregulation of certain hormonal systems such as 
the RAAS103 and the endothelin system104 all play a role in causing inflammation in 
CKD. Unpublished data from our department examining traditional and emerging 
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cardiovascular risk factors in patients with CKD has also confirmed that hsCRP is 
significantly, but weakly, associated with PWV (Fig 1.5). 
 










Oxidative stress is closely related to inflammation and is well documented in CKD. 
It appears to be present even in mild CKD and increases as glomerular filtration rate 
falls105. It is characterised by an imbalance between free radical exposure and 
antioxidant defence and is thought to play an important role in CVD development. 
With regard to the endothelium, increased production of oxidants inactivates NO, 
which in turn impairs endothelial function102.  
 
1.3 The endothelin system 
One major area of interest is that of the endothelin (ET) system, discovered in 1988. 
ET has been widely implicated in the development of both renal and cardiovascular 
disease and may well be an important marker of disease activity as well as a possible 
site for disease modification through its inhibition106. First described by Yanagisawa 
over two decades ago, the ET system comprises a family of 21-amino acid peptides 
with powerful vasoconstrictor and pressor properties107. Additionally, the 
predominant vascular isoform, ET-1, has pro-inflammatory, proliferative, pro-
fibrotic and hypertrophic effects104. Within the kidney, ET-1 has a role in salt and 
water homeostasis104. The ET system has been implicated in the pathogenesis of a 
number of diseases including hypertension, atherosclerosis, congestive heart failure, 
CKD, connective tissue disease and some forms of cancer. Thus the potentially wide 
r2 =0.05, p < 0.05
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clinical potential of ET blockade has led to intense research in this field, with a 
number of ET receptor antagonists (ETRAs) either approved for clinical use or under 
development.  
 
1.3.1 ET-1 synthesis and secretion 
Three human isoforms of ET have been isolated: ET-1, ET-2 and ET-3. These are 
encoded by distinct genes located, in man, on chromosomes 6, 1 and 20 
respectively108. In the case of ET-1, the dominant vascular isoform, the gene product 
is the 212-amino acid prepro-ET-1. This is cleaved intracellularly by a furin-like 
endopeptidase, to yield an inactive 38-amino acid precursor, big-ET-1108, which is 
then further cleaved by an endothelin-converting enzyme to generate the biologically 
active mature ET-1 peptide109 (Figure 1.6). Within the vasculature, the endothelial 
cell is the major site of ET-1 production though other cells are also capable of its 
production in health and disease, including vascular smooth muscle cells (VSMC), 
macrophages and fibroblasts110. Within the kidney, ET-1 is produced in relatively 
high amounts particularly in the inner medulla, which has been found to have the 
highest concentration of ET-1 of any body tissue111. It is synthesised by all 
glomerular cell types and by the tubules112.  
 
ET-1 synthesis, which is the key regulatory step in ET-1 generation, is modulated by 
a number of stimuli113. Synthesis is enhanced in response to low shear stress, 
turbulent blood flow, hypoxia, acidosis, cytokines, angiotensin II, adrenaline, insulin, 
cortisol and low-density lipoprotein. In contrast, high shear stress, NO, vasodilating 
prostaglandins and natriuretic peptides suppress ET-1 production113 (Figure 1.7). 
 
ET-1 acts primarily in an autocrine and paracrine manner. Up to 80% is released 
abluminally from endothelial cells towards VSMC114. Importantly, because of the 
polarised abluminal secretion of ET-1, its short half-life (~1 minute)115 in blood, and 
the sensitivity of blood levels to changes in clearance, plasma  ET-1 concentrations 




prepro-ET-1 (212 Amino Acids)




Figure 1.6 Synthesis and structure of the ET group and related 
sarafotoxin    
ET-2 and ET-3 differ from ET-1 by two and five amino acids while sarafotoxin 


























1.3.2 Endothelin Receptors 
The effects of ET-1 are mediated by two receptors: endothelin-A (ETA) and 
endothelin-B (ETB), both of which belong to the rhodopsin-like G-protein-coupled 
superfamily116, 117. Within the vasculature the ETA receptor is expressed 
predominantly on VSMC, cardiomyoctes and fibroblasts110. Its activation results in 
sustained vasoconstriction, cell proliferation and fibroblast activation. In contrast, the 
ETB receptor is predominantly expressed on endothelial cells. Its stimulation leads to 
vasodilatation through NO and prostacyclin release118. The ETB receptor is also 
present on VSMC where its activation contributes to ETA receptor-mediated 
vasoconstriction119. In addition, ETB receptors, particularly in the pulmonary 
circulation, act as the primary clearance mechanism for circulating ET-1. This occurs 
through ligand-receptor complex internalisation and intracellular degradation120. Up 
to 60% of circulating ET-1 is cleared following a single pass through the pulmonary 
vasculature120. (Figure 1.7)  
 
The human kidney has one of the highest concentrations of ET receptors in the 
body121. Renal ET-1 likely helps to control renal blood flow, glomerular 
haemodynamics, acid-base balance, and sodium and water homeostasis104, 122. Within 
the kidney, ET receptors are located in the renal vasculature, glomeruli and tubules. 
The ETA subtype is localised to VSMC, notably in the glomeruli, vasa recta and 
arcuate arteries, whereas ETB receptors are more numerous (ETB to ETA ratio 2:1) 
and widespread, with a high concentration in the collecting system123. Activation of 
ETA receptors leads to increase glomerular filtration pressures through efferent 
arteriolar constriction124. The ETB receptor promotes vasodilatation and appears to 
play a role in sodium and water homeostasis, inhibiting chloride transport in the 
medullary thick ascending limb of Henlé, thereby promoting natriuresis104. The 









ANP: atrial natriuretic peptide, BNP: brain natriuretic peptide, IL-1: 
interleukin-1, TGF-: transforming growth factor  
 
1.3.3 Endothelin-1 in normal physiology 
1.3.3.1 Vascular tone 
Up to 80% of ET-1 produced by endothelial cells diffuses through the basal wall of 
the vessel where it binds to both ETA and ETB receptors of VSMC which mediate the 
potent vasoconstrictor effects that are characteristic of ET-1114. The ETB receptor, 
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however, exerts a dual effect on vascular tone, as activation of the ETB receptors on 
endothelial cells stimulates the production of NO and vasodilatory cyclooxygenase 
metabolites, which in turn exert vasorelaxant effects on underlying VSMC126 (Figure 
1.7). In health, the predominant influence of ET-1 on vascular tone and basal BP is 
somewhat contentious. Systemic exogenous administration of ET-1 produces a 
biphasic response in BP, with transient hypotension followed by prolonged 
vasoconstriction and associated hypertension. The first phase corresponds to ETB 
receptor activation on endothelial cells whereas the hypertensive phase corresponds 
to smooth muscle activation predominantly through the ETA receptor though the ETB 
receptor on smooth muscle also likely plays an important role110. Studies using ET 
receptor antagonist, however, suggest that, in health at least, the ETB receptor may 
play a more important role in day-to-day vascular physiology. Acute administration 
of ETA or ETA/B antagonists causes a drop in peripheral resistance and arterial 
pressure. However, administration of selective ETB antagonist causes progressive and 
sustained vasoconstriction127.  This suggests that the more important physiological 
role of ET-1 is through action on the ETB receptors found on the endothelial cells126. 
 
1.3.3.2 Renal blood flow 
Exogenous ET-1 causes significant renal vasoconstriction. Indeed the renal 
vasculature is more sensitive to the vasoconstricting effects of ET-1 than other 
vascular beds128. Although total renal blood flow is reduced by exogenous ET-1 
there are regional variations within the kidney with cortical vasoconstriction and 
medullary vasodilatation126. Few studies have examined the effect of ET receptor 
antagonism on renal blood flow in health. Most studies to date have shown ETA and 
ETA/B antagonism to have no effect on renal blood flow suggesting that the ETA 
receptor has little to no role in maintaining renal vascular tone in health129-132. 
Unopposed ETB receptor antagonism, however, leads to significant renal 
vasoconstriction suggesting that the ETB receptor plays an important role in 
maintaining renal tone132. 
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1.3.3.3 Salt and water homeostasis 
There is now a large body of evidence to suggest that ET-1 has a role in the 
regulation of salt and water homeostasis126. Diuresis and natriuresis are explained by 
activation of the ETB receptors at the level of the medullary collecting ducts. The 
collecting ducts produce and bind more ET-1 than any other cell type in the body133.  
In vitro ET-1 and the ETB agonist sarafotoxin 6c lowers water permeability in 
vasopressin-stimulated inner medullary collecting epithelial cells134. In vivo this 
would lead to reduced water reabsorption in the collecting ducts and increased 
diuresis. Further work on the thick ascending loop of Henle has shown that ET-1, 
acting via the ETB receptor, inhibits chloride and sodium reabsortion135.  
 
Animal studies also support a role for the ETB receptor in sodium and salt handling 
within the kidney. Collecting duct ET-1 knockout mice have salt-sensitive 
hypertension, excessive weight gain and reduced urinary sodium excretion. All of 
these effects were reduced by amiloride and furosemide136. Collecting duct-specific 
knockout of the ETB receptor confirms the role of the ETB receptor, with these mice 
having salt dependent hypertension and impaired sodium excretion137. 
 
1.3.4 Role of ET-1 in Hypertension 
The potent effects of ET-1 on the vasculature have made it a plausible candidate 
mediator for the development of hypertension. The effects of ET-1 on BP appear to 
be at least partially dependent on sodium intake136, 137. To date, no endothelin 
antagonists have been licensed for the treatment of hypertension. However, a recent 
study in patients with resistant hypertension showed darusentan (a marginally 
selective ETA antagonist) had significant BP lowering effects that were maintained 
over the period of the study138. 
 
1.4 Endothelin Receptor Antagonists  
Endothelin receptor antagonists (ETRAs) are classified according to their selectivity 
for the ETA or ETB receptors and molecular structure. Selectivity is calculated from 
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in vitro competitive receptor assays. Those antagonists with an affinity >100-fold for 
the ETA receptor are said to be selective ETA antagonists. Those with 100-fold 
affinity are said to be ‘non-selective’, ‘dual’ or ‘mixed’ receptor antagonists. 
Bosentan, for example, has a 20:1 affinity for the ETA receptor and is therefore 
classified as a mixed ETRA139. Sitaxsentan, on the other hand, has a >6500:1 affinity 
for the ETA receptor and is therefore a selective ETA receptor antagonist140. Despite 
their differing receptor affinities, both bosentan and sitaxsentan belong to the 
sulphonamide class of ETRA. A list of selected ETRAs and their affinities can be 




Table 1.2 Selected ETRAs approved or currently under evaluation 
Modified from MacIntyre et al.141 
 
Compound Class Relative 
ETA/ETB 
selectivity 




Selective ETA  77-4000x Gilead Sciences Pulmonary artery hypertension 















Mixed ETA/B 20x Actelion Pulmonary artery hypertension 
















Selective ETA 130x Gilead Sciences Hypertension 




Selective ETA 80,000x Bristol-Myers 
Squibb 





Mixed ETA/B 110x GlaxoSmithKline Chronic Heart Failure 
Sitaxsentan 
TBC11251 




Chronic Heart Failure 





Mixed ETA/B 30x Actelion Chronic Heart Failure 






1.4.1.1Pharmacokinetics and pharmacodynamics of bosentan  
Bosentan is a mixed ETRA with a 20:1 affinity for the ETA receptor139. Its chemical 
structure can be seen in Figure 1.8. In healthy subjects, the absolute bioavailability of 
bosentan is around 50% with maximum plasma concentrations achieved at ~3 hours. 
It has a relatively short duration of action (terminal elimination half life ~5hours) 
requiring twice daily dosing. Steady state plasma concentrations are reached within 
3-5 days142.  
 
Bosentan is eliminated by biliary excretion following metabolism in the liver by the 
cytochrome P450 isoenzymes CYP2C9 and CYP3A4. Less than 3% of an 
administered oral dose is recovered in urine. Bosentan forms three metabolites and 
only one of these is pharmacologically active. This metabolite is mainly excreted 
unchanged via the bile. Bosentan is an inducer of CYP2C9 and CYP3A4 and 
possibly also of CYP2C19 and the P-glycoprotein142. In patients with significant 
renal impairment (creatinine clearance 15–30mL/min), plasma concentrations of 
bosentan decreased by ~10%. No dose adjustment is required in patients with renal 
impairment. 
 












1.4.1.2 Clinical Trials 
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Bosentan has been extensively studied in the management of pulmonary artery 
hypertension  (PAH) where it has been found to be both safe and effective143. It has 
also been shown to be of benefit in reducing the number of new digital ulcers in 
patients with systemic sclerosis144, 145. Furthermore, it is effective in reducing BP in 
patients with mild to moderate systemic hypertension, with BP reductions similar to 
those expected from ACE inhibition146. 
  
1.4.1.3 Bosentan tolerability and safety 
Bosentan is well tolerated. Side effects most commonly attributed to treatment, after 
placebo correction, include flushing (4.9%), abnormal hepatic function (3.8%), leg 
oedema (3.3%), headache (3%) and anaemia (2.4%)143.  Of these side effects the 
most serious is elevation of liver enzymes and is the most common cause for 
discontinuation of the drug. The incidence of liver enzyme elevation greater than 
three times the upper limit of normal occurs in between 8-14% of patients, with drug 
discontinuation rates of 4% by 30 months143. The development of fluid retention and 
peripheral oedema can also be problematic with bosentan and to an extent is dose 
dependent. It is likely at least in part due to functional ETB blockade within the renal 
tubules leading to salt and fluid retention. 
 
A class effect of ETRAs is their teratogenicity, an effect most apparent in the first 
trimester of pregnancy. As such, women of childbearing age are required to use 
reliable contraception and monthly pregnancy testing is advised.  
 
1.4.1.4 Drug interactions 
Bosentan is an inducer of the cytochrome P450 isoenzymes CYP2C9 and CYP3A4. 
As such, other medications which use this pathway for metabolism, such as warfarin 
will be metabolised more quickly and doses may need adjustment142. 
 
1.4.1.5 Licensing 
Bosentan is licensed both by the European Medicines Agency and Food and Drug 
Administration for the treatment of idiopathic PAH. In Europe it is also licensed for 
the treatment of digital ulceration in scleroderma. 
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1.4.2 Sitaxsentan 
1.4.2.1Pharmacokinetics and pharmacodynamics of sitaxsentan  
Sitaxsentan (also known as sitaxentan) is a highly selective ETA receptor antagonist 
with ~6500 times greater affinity for the ETA than the ETB receptor 140.  Its chemical 
structure can be seen in Figure 1.9. It has high oral bioavailability (>90%) and rapid 
absorption, reaching maximum plasma concentrations at 1-4 hours. It has a long 
duration of action (terminal elimination half life ~10 hours) allowing it to be given as 
a once-daily treatment.  At the standard 100mg dose, sitaxsentan displays linear 
elimination in humans, with no increase in mean maximum plasma concentrations 
over a 12-week dosing period147. Steady state plasma concentrations are achieved at 
~6 days. At 300mg, however, non-linear elimination is seen, with disproportionately 
higher plasma concentrations (12-fold increase compared to 100mg dosing)147, which 
may ultimately lead to higher rates of adverse effects. 
 
Sitaxsentan is extensively metabolized (only 1% of the oral drug is excreted 
unchanged) primarily via cytochrome CYP2C9 and CYP3A4. Its primary 
metabolites have less than one-tenth the activity of the parent drug. In humans  ~55% 
of the metabolites of sitaxsentan are excreted in the urine with the rest being 
eliminated in faeces148. However, there is no evidence that renal impairment has any 
effect on the pharmacokinetics of the drug149. 
 
1.4.2.2 Clinical Trials 
Sitaxsentan underwent a number of phase III clinical studies examining its role in the 
management of PAH and are listed in Table 1.3. They showed sitaxsentan to be 
effective in the management of PAH with significant improvements in exercise 
capacity, functional class and pulmonary vascular haemodynamics while increasing 
time to clinical worsening. Its effects appeared long lasting, with studies suggesting 
continued benefit at 2 years of treatment. Early data also suggested that selective 
ETA receptor blockade is suitable substitute for patients who poorly tolerate, or gain 
no benefit from, bosentan therapy.  
 














1.4.2.3 Sitaxsentan tolerability and safety  
Treatment with sitaxsentan is generally well tolerated. Side effects most commonly 
attributed to treatment, after placebo correction, include headache (5.5%), nasal 
congestion (5.5%), nausea (3%) and peripheral oedema (1%) 147, 150.  
 
Liver function abnormalities appear to be a class effect of the sulphonamide ETRAs 
and, to a degree, dose related. During the initial open label study of sitaxsentan that 
used large doses of drug (up to 1g daily), 7 out of 20 patients experienced 
asymptomatic transaminase elevations151. During the extension arm of this study, one 
of these patients subsequently developed severe acute hepatitis, which resolved on 
stopping sitaxsentan.  A further patient in this arm of the study developed acute 
fulminant hepatitis at 16 weeks of treatment, and despite discontinuation of 
sitaxsentan, died. More recent studies however (STRIDE-1 and STRIDE-2) 
demonstrated a far lower incidence of elevated transaminases with lower doses of 
sitaxsentan147, 150. Combining the data from both studies, elevated transaminases 
(classed as 3 times the upper limit of normal) occurred in ~2% of patients taking 
100mg per day compared to 5% in the placebo arm over an 18-week period. 
Furthermore, an interim analysis from the STRIDE-2X study suggested, that over a 
1-year period, sitaxsentan was associated with a significantly lower incidence of 
abnormal liver function tests compared to bosentan (4% and 14% respectively)152. 
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Early data from STRIDE-3 and STRIDE-6, studies enrolling patients who have had 
to discontinue bosentan therapy due to raised transaminases, suggested that 
recurrence of altered liver function tests on sitaxsentan was low (13% at 18 
weeks)153.  
 
Mild reductions in haemoglobin and haematocrit are seen with ETRAs and likely 
represent fluid retention. A fall in haemoglobin was reported in both sitaxsentan 
treatment arms in the STRIDE-1 study (1.0g/dL in the 100mg group vs. 1.6g/dL in 
the 300mg group)147. Similar findings were reported in STRIDE-2 with 0.4g/dL 
reduction in the 50mg sitaxsentan arm and a 0.7g/dl reduction in both 100mg 
sitaxsentan and open-label bosentan arms150.  
 
Like all ETRAs sitaxsentan is teratogenic and as such, women of childbearing age 
are required to use reliable contraception and advised to undergo monthly pregnancy 
tests.  
 
1.4.2.4 Drug interactions 
Sitaxsentan has been shown to exert an inhibitory response on hepatic cytochrome 
CYP2C9 and to a lesser extent on CYP3A4/5. As such, metabolism of warfarin may 
be reduced, and its actions prolonged. This is an important interaction as many 
patients with a diagnosis of PAH will be on thromboprophylaxis. Results, however, 
from STRIDE-2 suggest that after an 80% initial dose reduction of warfarin upon 
commencement of sitaxsentan, further warfarin changes were equally frequent for 
patients treated with sitaxsentan, bosentan or placebo, suggesting no greater 
complexity in management150, 154. Although the pharmacokinetics of cyclosporine A 
(metabolised by CYP3A4/5) are not altered by sitaxsentan, cyclosporine has been 
shown to alter the pharmacokinetics of sitaxsentan, with pre-dose levels of 
sitaxsentan increasing 6 fold. As such, concomitant use is contraindicated on the 
current license. There have been no significant interactions seen with nifedipine, 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Sitaxsentan was initially classified in September 2004 as an orphan medicinal 
product by the European Agency for the Evaluation of Medicinal Products (EMEA) 
for the treatment of PAH. In June 2006, however, the Committee for Medicinal 
Products for Human Use of the European Medicines Agency recommended its 
approval at a dose of 100mg for the improvement of exercise capacity in patients 
with PAH functional class III. At this time sitaxsentan was still classed as an orphan 
drug in the USA with the FDA requesting further phase III data prior to any licence 
being granted. 
 
In December 2010, Pfizer’s voluntarily withdraw sitaxsentan from the market 
worldwide following two new cases of fatal liver injury. 
 
1.5 Aims and hypotheses 
In a series of acute and chronic studies, this thesis explores CVD risk in patients with 
CKD and examines the impact of ET-1 and its antagonism. 
 
Study  1: Cardiovascular risk in patients in remission from immune-
mediated inflammatory renal disease (Chapter 3) This study examined AS 
in patients with SVV and renal involvement, comparing these to a cohort of patients 
with non-inflammatory renal disease.  
 
Study  2: Investigation of arterial stiffness in newly diagnosed immune-
mediated renal disease (Chapter 4) This study examined AS in a cohort of 10 
patients with immune-mediated inflammatory renal disease following them through 
the first 1-year of treatment. 
 
Study 3: Investigation of functional ETB receptor antagonism after 
bosentan and sitaxsentan in healthy men (Chapter 5) This study sought to 
clarify the functional ETB receptor blockade produced by standard clinical doses of 
the ET receptor antagonists bosentan and sitaxsentan. The effect of these drugs on 
plasma ET-1 concentrations and their ability to block ET-3 mediated vasodilatation 
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as functional markers of ETB receptor blockade was studied. The information from 
this study was used to verify the ETA selectivity of sitaxsentan 
 
Study 4: The effects of oral acute and chronic selective ETA receptor 
antagonism on systemic and renal haemodynamics in CKD (Chapter 6) 
This study sought to examine the effect of acute and chronic ETA receptor blockade 
in a cohort of patients with CKD, examining its effect on systemic and renal 
haemodynamics. 
 
Study 5: The effects of selective chronic ETA receptor antagonism on 
selected markers of renal and cardiovascular disease progression 
(Chapter 7) This study examined the effects of chronic dosing of a selective ETA 
antagonist in a cohort of patients with CKD looking at its effects on risk factors of 































































All studies were performed in the University of Edinburgh’s Clinical Research Centre 
with the approval of the local research ethics committees and the written informed 
consent of each subject. The investigations conformed to the principles outlined in the 
Declaration of Helsinki.  
 
All subjects abstained from alcohol, nicotine and caffeine-containing products for 24 
hours, and had a light breakfast, before attending on each study day. All studies were 
carried out in a quiet, temperature-controlled room, at 22-24C, with the subject 
recumbent throughout, except when voiding urine, during which they were allowed to 
stand. 
 
Healthy subjects taking any medications in the previous 2 weeks were excluded from the 
study. Patients continued taking their normal medications up to and including each study 
day with the exception of diuretics, which they omitted that morning.  
 
2.1  Drug administration 
2.1.1 Locally active doses - intra-arterial administration 
The brachial artery of the non-dominant arm was cannulated under local anaesthesia 
(1% lignocaine; Astra Pharmaceuticals, Stockholm, Sweden) with a 27 SWG steel 
needle (Cooper's Needle Works, Birmingham, UK) attached to a 16G epidural catheter 
(Portex Ltd, Hythe, Kent, UK), and patency was maintained by infusion of physiological 
saline (0.9%; Baxter Healthcare Ltd, Thetford, UK) at 1 ml/min. Saline was infused for 
30 min prior to the infusion of ET-3. 
 
2.1.2 Systemically active doses - intravenous administration 
For systemic intravenous administration, study drugs were infused via an 18 SWG 
cannula sited in an antecubital vein. Para-aminohippurate acid and Inutest were diluted 
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in dextrose (5%; Baxter Healthcare Ltd, Thetford, UK) and infused intravenously at a 
constant rate of 2 ml/min.  
 
2.2 Drugs  
2.2.1 Endothelin-3 
Compared to ET-1, which has equal affinity for the ETA and ETB receptor (Ki 0.6nmol/L 
and 0.12nmol/L respectively), ET-3 has a greater affinity for the ETB than the ETA 
receptor (Ki 0.06nmol/L vs. 140nmol/L) and as such can be used as a relatively selective 
ETB agonist160. ET-3 (Merck Chemicals Ltd), dissolved in physiological saline, was 
administered intra-arterially at a dose of 60pmol/min for 5 minutes. This dose was based 
on previous work showing, in vivo, that 60pmol/min caused significant early forearm 
vasodilatation, suggesting functional stimulation of the endothelial ETB receptor161. 
 
2.2.2 Bosentan 
Bosentan (Actelion Pharmaceuticals Ltd, Basel, Switzerland) is used in these studies at a 
dose of 125mg twice daily, the recommended maintenance dose in pulmonary arterial 
hypertension162. Bosentan is a dual ET-1 receptor antagonist with affinity for both ETA 
and ETB receptors139. Its oral bioavailability is ~50% and is largely unaffected by food. 
It reaches maximum plasma concentrations approximately 3 hours after ingestion and 
has a relatively short duration of action (terminal half-life ~ 5 hours) requiring twice 
daily dosing163. Steady state plasma concentrations are achieved in 3-5 days163. Bosentan 
is metabolized by cytochrome P450 (CYP) 2C9 and CYP3A4 into three metabolites, Ro 
48-5033(major metabolite), Ro 47-8634, and Ro 64-1056. Only Ro 48-5033 is 
metabolically active, accounting for up to 20% of drug activity. Oral bosentan is 
eliminated largely via faeces in healthy adults, mainly as Ro 48-5033; less than 3% of a 




Sitaxsentan (Encysive Pharmaceuticals Inc, Houston, USA) is used in these studies at a 
dose of 100mg once daily. Sitaxsentan is a highly selective, orally active ETA receptor 
antagonist with around 6500 times greater affinity for the ETA than the ETB receptor140. 
It has high oral bioavailability (>90%) and rapid absorption, reaching maximum plasma 
concentrations at 1-4 hours. It has a long duration of action (terminal elimination half 
life ~10 hours) allowing it to be given as a once daily treatment. At the standard 100mg 
dose, sitaxsentan displays linear elimination in humans, with no increase in mean 
maximum plasma concentrations over a 12-week dosing period147. Steady state plasma 
concentrations are achieved at ~6 days. At 300mg, however, non-linear elimination is 
seen, with disproportionately higher plasma concentrations (12-fold increase compared 
to 100mg dosing)147 that may ultimately lead to higher rates of adverse effects. 
Sitaxsentan is extensively metabolized (only 1% of the oral drug is excreted unchanged) 
primarily via cytochrome CYP2C9 and CYP3A4. Its primary metabolites are less than 
one-tenth as active as the parent drug. In humans ~55% of the sitaxsentan’s metabolites 
are excreted in the urine with the rest being eliminated in faeces148. There is no evidence 
that renal impairment has any effect on the pharmacokinetics of the drug149. 
 
2.2.4 Nifedipine 
Nifedipine 30mg LA (Adalat, Bayer) was used as active BP control in Chapters 6 and 7, 
and was administered orally. Nifedipine is a calcium antagonist of the 1,4-
dihydropyridine type. It reduces the transmembranal influx of calcium through the slow 
calcium channels into the cell, acting particularly on the cells of the myocardium and 
smooth muscle cells of the peripheral resistance vessels. The resultant action is of 
arterial vasodilatation and subsequent reduction in BP164. 
 
Adalat LA is formulated to provide nifedipine at a constant rate over a 24-hour period. 
This occurs via a membrane-controlled, osmotic push-pull process. Nifedipine is almost 
completely absorbed in the gastro-intestinal tract and after oral administration it is 
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metabolised in the gut wall and the liver by oxidative processes. The kidneys 
predominantly excrete its metabolites, with 5-15% being excreted in bile and faeces. 
There is no difference in the pharmacokinetics of nifedipine between healthy subjects 
and those with renal impairment and as such no dose adjustment is required164.  
 
2.2.5 Para-aminohippurate acid 
Para-aminohippurate acid (Clinalfa AG) was used for the measurement of renal blood 
flow using standard clearance techniques165 (Chapter 4). It is an amide derivative of the 
amino acid glycine and para-aminobenzoic acid that is not naturally found in man. Para-
aminohippurate acid is an inert and non-toxic compound that only reaches the kidney via 
the blood stream and is filtered by the glomerulus and excreted by the proximal tubules. 
The extraction by the kidneys in a single transit is not complete (the full criteria for a 
marker of renal blood flow (RBF) by clearance) but about 80-90%, thus measurements 
are quoted as "effective" renal plasma flow (ERPF). 
 
Para-aminohippurate acid was administered as a bolus loading dose of 0.4 g in 100 ml 
dextrose 5 over 15 min, and a maintenance infusion of 6.6 g/L at a rate of 2 ml/min. For 
subjects with a calculated GFR < 50 ml/min, the maintenance dose was reduced by one-
third, and by two-thirds for those with a GFR < 30` ml/min. This regimen was based on 
previous work by Goddard et al.132.   
 
2.2.6 Sinistrin 
Sinistrin (Inutest, Fresenius Pharma, Austria GmbH) was used for the measurement of 
glomerular filtration rate (GFR) by standard clearance techniques165 (Chapter 6). 
Sinistrin, like inulin, is a naturally occurring sugar polymer of the fructan group. It has a 
molecular weight of ~3,500 daltons and is inert and non-toxic. It is not protein-bound, is 
freely filtered at the glomerulus, is neither secreted not reabsorbed within the tubules, 
nor metabolised within the kidney and hence fulfils the criteria for the measurement of 
GFR by clearance measurement.  Sinistrin differs from inulin due to its high solubility in 
water (also in cold water) and improved alkaline stability. It has identical renal clearance 
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to that of inulin. The quantitative determination of sinistrin in urine and blood plasma is 
identical to that of inulin166.  
 
Sinistrin was administered as a bolus loading dose of 3.5 g in 100 ml dextrose 5 over 15 
min, and a maintenance infusion of 10 g/L at a rate of 2 ml/min. For subjects with a 
calculated GFR <40 ml/min, doses were reduced by a third. A steady-state concentration 
of sinistrin in the extracellular compartment is reached within approximately 70 
minutes166.  
 
2.3  Haemodynamic measurement 
2.3.1 Blood pressure  
BP was recorded in duplicate at each time-point using a well-validated semi-automated 
non-invasive oscillometric sphygmomanometer (Omron HEM-705CP)167. Recordings 
were required to be within 10 mmHg of each other (systolic and diastolic). If not, BP 
was repeated until two consecutive readings did fulfil these criteria. During forearm 
studies (Chapter 5), BP was recorded in the dominant arm (i.e. not in the arm with intra-
arterial cannulation.) 
 
2.3.2 Arterial stiffness 
Pulse wave velocity (PWV) is a widely accepted indicator of AS.168 PWV was measured 
using the SphygmoCor® system (SphygmoCor® Mx, AtCor Medical, Sydney, 
Australia, version 6.31) with the use of a high-fidelity micromanometer (SPC-301, 
Millar Instruments, Texas, USA) and electrocardiogram (ECG) gating to attain the pulse 
waves from both proximal (carotid artery) and distal (femoral artery) sites. The PWV is 
calculated from the transit time between the two sites relative to the R-wave within the 
ECG complex using the ‘foot-to-foot method’ and the intersecting tangent algorithm. 
The distance travelled was calculated using the following: the distance from the level of 
the sternal notch to the femoral location of the micromanometer minus the distance from 
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the level of the sternal notch to the carotid pulse.  PWV was calculated using the 
following: 
 
PWV (m/s) = Distance travelled / wave transit time 
 
PWV was recorded in duplicate with values required to be 0.5 m/s of each other. If not, 
further recordings were made until two consecutive readings did fulfil the criterion.  
 
The SphygmoCor apparatus was also used to measure the radial augmentation index. 
This was derived from averaged radial artery waveforms. Central augmentation index 
(cAIx), used as an additional measure of AS, was calculated from central aortic 
waveforms, which were derived by applying a generalised transfer function to the 
directly measured radial waveforms. All pulse wave analysis (PWA) measurements were 
made in duplicate with cAIx values within 5% of each other. When this criterion was not 
met, further recordings were made until two consecutive readings did fulfil the criterion. 
The quality control for PWA including average pulse height >100, pulse height variation 
<5%, and diastolic variation <5% were followed. As cAIx is partly dependent on heart 
rate all recordings were corrected to a heart rate of 75bpm. 
 
2.3.3 Flow mediated Dilatation (FMD) 
FMD is an endothelium-dependent process by which arterial dilatation occurs in 
response to increased shear stress169.  This dilatation is almost entirely due to NO release 
and is abolished with L-NMMA infusion170. In chapter 3 of this thesis FMD of the 
brachial artery was measured. With individuals in a supine position and their arms 
outstretched perpendicular to the body, the brachial artery was imaged longitudinally 
with B-mode ultrasound (Acuson XP 128, Siemen plc, Bracknell, UK) 5 cm above the 
antecubital fossa using a linear array transducer with an imaging frequency of 11 MHz. 
The ultrasound probe was held in place with a stereotactic clamp throughout the study 
(see figure 2.1). A segment with clear anterior and posterior intimal interfaces between 
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the lumen and vessel wall was selected as the area to be analysed for the change of the 
arterial diameter. Every 3 seconds, end-diastolic frames (ECG R-wave triggered) were 
acquired on a computer equipped with DT-3152 progressive scan frame grabber (Data 
Translation Ltd, Basingstoke, UK) and image acquisition software (CVI Acquisition 
version 1.5, Information Integrity Inc, USA).  
 
Baseline diameter was recorded for 1 minute. To create a flow stimulus in the brachial 
artery, a BP cuff, which was placed around the upper forearm, was inflated to 50 mmHg 
above SBP in order to occlude blood flow into the forearm for 5 minutes. Following 
deflation of the cuff the artery was scanned for a further 5 minutes. All the ultrasound 
recordings were stored on videotape. Brachial artery diameter was calculated off-line 
from the stored images using semi-automated wall tracking software (Brachial Analyzer, 
Medical Imaging Application, Iowa, USA). FMD was reported as a percentage change 
of the brachial artery diameter from baseline (FMD%). 
 




2.3.4 Forearm blood flow 
FBF was measured by venous occlusion plethysmography with mercury-in-silastic strain 
gauges applied to the widest aspect of each forearm161, 171. The hand was excluded 
during periods of blood flow study by inflation of wrist cuffs to 220 mmHg. An upper 
arm cuff was intermittently inflated to 40 mmHg for 10s in every 15s to temporarily 
prevent forearm venous outflow and obtain plethysmographic recordings. Voltage 
output from a dual-channel Vasculab SPG 16 strain gauge plethysmograph (Medasonics 
Inc) was transferred to a Macintosh personal computer (Macbook Pro, Apple Computer 
Inc, Cupertino, CA, USA) using a MacLab analogue digital converter and Chart 
software (v. 3.2.8; both from AD Instruments, Castle Hill, NSW, Australia). Calibration 
was achieved using the internal standard of the Vasculab plethysmography units. The 




Figure 2.2 Experimental setup of forearm blood flow 
 
 
2.3.5 Clearance Studies 
Effective renal blood flow (ERBF) and GFR were measured by standard clearance 
techniques165 (Chapter 6). On each study day, an 18 standard wire gauge (SWG) cannula 
was sited in an antecubital vein in each arm. Diuresis was induced by 500 ml 5% 
dextrose over 30 min through the left arm cannula. After 15 min, the loading doses of 
para-aminohippurate acid & sinistrin were administered through the same cannula. 
Thereafter, maintenance infusions of para-aminohippurate acid and sinistrin, and 5% 
dextrose at 180 ml/hr continued throughout the study. Urine was collected by 
spontaneous voiding every 60 min. A 2.5-hour period was allowed for water, sinistrin 
and para-aminohippurate acid equilibration before baseline measurements, made over a 
1 hour period. BP, cardiac output (CO) and heart rate (HR) were recorded every 15 min. 
Each collection period lasted 1 hour with urine being collected (spontaneous voiding) at 
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the beginning and end of each period with blood samples for para-aminohippurate acid, 
sinistrin and haematocrit being collected 30 min into each period. Each study day had 4 
clearance periods.  
 
2.3.6 Cardiac Output and Heart Rate 
Cardiac output (CO, L/min) and heart rate (HR, bpm) were recorded using a well 
validated non-invasive bioimpedance technique (NCCOM3; BoMed Medical 
Manufacturer Ltd, Irvine, California, USA)172, 173. A constant sinusoidal current is 
applied through dual electrodes situated at the root of the neck bilaterally and to the 
lateral aspect of the trunk at the level of the lower chest. The changes in bioimpedance to 
this current are related to cardiac events and to blood flow. CO is estimated from the 
measures of bioimpedance by the Sramek-Bernstein formula, adapted from the original 
formula of Kubicek173. HR is counted directly from detection of the cardiac electrical 
cycle. Each reading is the average of 15 consecutive beats. Four such readings were 
recorded for each measurement of CO and HR. 
 
2.3.7 Ambulatory blood pressure monitoring  
Ambulatory BP was measured at the brachial artery using a validated SpaceLabs 90217 
ambulatory BP monitor174. Measurements were taken every 30 minutes for 24 hours. 
 
2.4 Measurements of Renal Function 
Glomerular filtration is widely considered the best overall marker of kidney function in 
both health and disease175. It cannot be measured directly in humans, but can be 
determined by plasma clearance of a filtered marker in to the urine. Ideally, this marker 
should be inert, not protein bound, be freely filtered by the glomerulus and not actively 
secreted, reabsorbed or metabolised by the kidneys.  A number of exogenous and 
endogenous have been proposed. Within this thesis I used both sinistrin (exogenous 




Urinary clearance of inulin (or sinistrin) is considered the gold standard measurement of 
GFR. Inulin is not protein bound, is freely filtered at the glomerulus, is neither secreted 
not reabsorbed within the tubules, nor metabolised within the kidney and hence fulfils 
the criteria for the measurement of GFR by clearance measurement. Once steady state is 
reached, after around 70 minutes166, repeated timed urine and blood samples are 
collected and GFR derived from the concentration of inulin and plasma and urine and 
the urinary flow rate (see section 2.5.2.2).  
 
2.4.1 Creatinine 
Creatinine is the most commonly used endogenous marker of glomerular filtration. It is 
primarily formed within skeletal muscle with a small contribution from dietary 
ingestion176.  With a mass of 113 daltons it is freely filtered by the glomerulus and is not 
reabsorbed by the tubules. It is, however, limited by the fact that its production varies 
with person and time dependent on muscle mass and diet. It is also actively secreted by 
the tubules; hence, creatinine clearance exceeds GFR177.  
 
Numerous equations using creatinine have been created to try and estimate GFR more 
accurately.  Of these the Cockcroft & Gault and MDRD equations have been the most 
evaluated and studied, and have been used within this study.  
 
2.4.3  Cockcroft & Gault equation  
The Cockcroft & Gault (C&G) formula was developed in 1973 based on the data from 
249 men with a wide range of age and renal function and measures creatinine clearance 
and is based on 4 variables: age, sex, weight and serum creatinine level178. Creatinine 
clearance = [140 - age (years)] x weight (kg) x (0.85 if female) / serum creatinine.178 
Creatinine clearance can then be further corrected by body surface area (BSA): BSA = 
[71.84 x weight (kg)0.425 x height (cm)0.725] / 10,000 as defined by Du Bois, et al. 179. As 
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previously mentioned creatinine clearance always overestimates GFR due to creatinine 
secretion by the tubules.  
 
2.4.4  MDRD equation 
The MDRD  (Modification of Diet in Renal Disease study) equation was developed in 
1999 based on creatinine from 1628 patients with CKD21. The initial equation was based 
on 6 variables: age; sex; ethnicity; and serum levels of creatinine, urea, and albumin21. It 
has since been simplified to a 4-variable equation consisting of age, sex, ethnicity, and 
serum creatinine concentration180. GFR (mL/min/1.73 m2) = 175 × (serum creatinine)-
1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if Black).  
 
 
2.4.5 Limitations of Cockcroft & Gault and MDRD equations 
The MDRD equation and C&G equations appear to be accurate in non-hospitalised 
patients with CKD, though C&G is less accurate in the elderly and obese177. Both 
MDRD and C&G equations are less accurate in those without kidney disease though 
C&G may be slightly more accurate than the MDRD equation when used to assess mild 
renal insufficiency.181, 182 
 
2.5 Assay 
At pre-specified time points, venous blood was collected via an 18 SWG cannula for 
plasma measurements. Blood was collected into serum-gel tubes (Sarstedt) for the 
measurement of serum sodium, and into ethylenediaminetetraacetic acid (EDTA) tubes 
(Sarstedt) for all other plasma measurements. Blood was centrifuged immediately at 
2,500 g for 20 min at 4°C except for haematocrit which was measured on whole blood. 
Samples were stored at –80°C until analysis.  20 ml aliquots of urine from each voiding 
were collected into plain tubes for the urinary measurements. At pre-specified time 
points, 20ml aliquots of urine were also collected into plain tubes containing 2.5ml of 
50% acetic acid for the measurement of urinary ET-1. 
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2.5.1  Plasma and urinary ET-1 
After extraction183, ET-1 was determined by radioimmunoassay using rabbit anti-human 
ET-1 (Bachem UK Ltd, St Helens, UK) 132. The mean recovery of ET-1, from extraction 
to assay, was >90%. The intra- and inter-assay variations were 6.3 and 7.2%, 
respectively. The cross-reactivity of the antibody was 100% with ET-1, 7% for both ET-
2 and ET-3, and 10% with big ET-1. 
 
2.5.2  Plasma & urinary para-aminohippurate acid 
Para-aminohippurate acid was determined by high performance liquid chromatography 
(HPLC) with fluorescence detection. Plasma samples were deproteinised with equal 
volumes of 6% perchloric acid and, after centrifugation at 1000 g for 10 min, 
supernatant was diluted by 1/40 with deionised water. Urine samples were diluted 
1/4000. Dihydroxybenzylamine hydrobromide (DHBA) was used as an internal 
standard. Samples were injected into the HPLC column. The HPLC system consisted of 
a Waters 510 HPLC pump, WISP (Waters Intelligent Sample Processor) and Spherisorb 
S5 ODS column (Waters Ltd, Watford, Herts. UK) with detection by an LS-5 
fluorometric detector (Perkin-Elmer Ltd, Beaconsfield, Bucks, UK), with excitation and 
emission wavelengths of 280 nm and 360 nm, respectively. The mobile phase consisted 
of 0.1 molar citrate acetate buffer containing 100 mg/L octane sulphonic acid. 
 
2.5.3  Plasma & urinary sinistrin 
Sinistrin was determined by spectrophotometry after hydrolysis to fructose. Plasma 
samples were deproteinised with equal volumes of 6% perchloric acid and after 
centrifugation at 1000 g for 10 min supernatant was decanted. Urine was diluted 1/20 
with 3% perchloric acid. Resorcinol (1.5 g dissolved in 1 l of ethanol) and HCl/FeCl3 
solution (7.5 mg FeCl3 dissolved in 1 l of molar hydrochloric acid) were added in a 6:6:1 
ratio to the plasma/urine. The samples were then vortexed and incubated at 80oC for 40 
min. Sinistrin concentrations were then determined against standard curves by 
absorption spectrophotometry at 480 nm. 
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2.5.4  Haematocrit 
Haematocrit was measured using a Coulter counter. 
 
2.5.5  Plasma and urinary sodium 
Urinary and plasma sodium concentrations were measured using an ion-selective 
electrode.  
 
2.5.6  Urinary protein 
Urine protein was measured using a colorimetric method with pyrogallol red184. 
 
2.6 Data analysis  
Descriptive statistics are presented as mean  SEM unless otherwise indicated. 
Microsoft Excel 2004 for Windows and SPSS Statistics (Version 19, IBM New York, 
USA) were used for statistical analyses. For categorical data, means were compared by 
one-way analysis of variance (ANOVA), Kruskal-Wallis test, unpaired Student’s t-test, 
and Mann-Whitney test where appropriate. Correlation coefficients were calculated 
using the Pearson method. Stepwise linear regression was used for multivariate analysis. 
A p value of < 0.5 was considered significant. 
 
2.6.1  Forearm blood flow 
Plethymographic data were extracted from Chart (v5.0.2 PowerLab 2003) data files and 
forearm blood flows were calculated for individual venous occlusion cuff inflations by 
use of a template spreadsheet (EXCEL 2004 for Macintosh; Microsoft Corporation). The 
last five measurements from each 3-minute recording period were averaged for the 
infused and non-infused arm. However to detect early, transient, changes in blood flow, 
every recording during a 13-minute period of continuous FBF measurement was 
analyzed. To reduce variability of blood flow data, the ratio of flows in the two arms 
was calculated for each time point. FBF results were calculated as the ratio of flow 
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between the infused and non-infused arms and shown as percentage change from 
baseline185. The percentage change in forearm blood flow following drug administration 
was calculated as follows: 
                   
100% x      F(i)d/F(ni)d – F(i)v/F(ni)v 
              F(i)v /F(ni)v 
 
where F(i) and F(ni) represent measured blood flows in the infused and non-infused 
arms respectively during periods of drug (d) and vehicle (v) administration186. 
 
2.6.2  Systemic & Renal data 
Data were stored and analysed using the Microsoft Excel data analysis package (EXCEL 
2004 for Macintosh; Microsoft Corporation).  
 
2.6.2.1 Blood Pressure 
BP at each time point was calculated as the mean of 2 recordings and represented as 
mean arterial pressure (MAP). MAP was calculated as follows: 
 
Diastolic BP +  (Systolic BP – Diastolic BP) 
                       3 
2.6.2.2 Renal blood flow, glomerular filtration and sodium excretion 
ERBF and GFR were calculated from para-aminohippurate acid and inulin clearance, 
respectively. Urinary sodium excretion and fractional excretion were calculated from 
plasma and urinary sodium and inulin concentration and urinary flow rates (Table 2.1) 
 
 
Table 2.1 Calculations used for renal data 
Measurement Calculation Units 
Glomerular Filtration Rate 
(GFR) 




Effective Renal Plasma Flow 
(ERPF) 
uPAH x UFR 
pPAH 
ml/min 










Effective Filtration Fraction 
(EFF) 
GFR  x 100 
ERPF 
% 
Urinary Flow Rate 
(UFR) 
Urinary volume 
Time of collection 
ml/min 
Urinary Sodium Excretion 
(UNaV) 
uNa x UFR mol/min 
Fractional Excretion of Sodium 
(FeNa) 
uNa x pIn 
pNa    uIn 
 
PAH: Para-aminohippurate acid 
2.6.2.3 Bioimpedance  
Cardiac output was recorded using a well validated non-invasive bioimpedance 
technique (NCCOM3; BoMed Medical Manufacturer Ltd, Irvine, California, USA)172, 
173. Cardiac output is calculated by detecting changes in the body's impedance to a small 
electrical current. Blood and tissues both impede electrical current, however, within the 
time frame of the cardiac cycle, only the volume of blood within the chest changes. This 
resulting change in thoracic blood volume causes changes in impedance, which can then 
be used to calculate cardiac output with the use of computer algorithms. Bioimpedance 
data at each time point were calculated as the mean of four recordings, each the average 
of 15 consecutive heartbeats. Data were corrected using body surface area to give 
cardiac index (CI) for direct comparison of subjects. Systemic Vascular Resistance 
Index (SVRI) was derived from BP and CI data using the following equation: 




Chapter 3: Cardiovascular risk in 






Systemic connective tissue diseases are associated with an increased risk of 
cardiovascular disease (CVD). This may in part be driven by chronic inflammation. 
Patients with small vessel vasculitides which effect the kidney, such as Anti-neutrophil 
cytoplasmic antibody (ANCA) associated vasculitis and systemic lupus erythematosus 
(SLE), may be expected to confer greater CVD risk through a combination of classic 
CVD risk factors, renal impairment and chronic inflammation than in those with renal 
impairment alone. The aim of this study was to determine whether inflammation and 
renal impairment may impact on arterial stiffness (AS) and endothelial dysfunction in a 
cohort of patients in remission from small vessel vasculitis. 
 
Methods 
Aortic pulse wave velocity (PWV), central augmentation index (cAI) and flow-mediated 
dilatation (FMD) were assessed in 22 patients with a diagnosis of small vessel vasculitis 
who were currently in remission.  
 
Results 
PWV was significantly positively related to age (r2 = 0.40, p < 0.01) systolic BP (r2 = 
0.31, p < 0.01), C-reactive protein (CRP) (r2 = 0.32, p < 0.01), triglycerides (r2 = 0.51, p 
< 0.01), and urate (r2 = 0.01, p < 0.01), and inversely related to eGFR (r2 = 0.21, p < 
0.05). Following multiple regression analysis only age, systolic BP, and triglycerides 
remained independently associated with PWV. AIx was positively related to age (r2 = 
0.42, p <0.001) and this remained the case following multiple regression analysis. FMD 
was inversely related to age (r2 = 0.27, p < 0.05) and waist:hip ratio (WHR) (r2 = 0.29, p 
< 0.05) and positively related to protein:creatinine ratio (PCR) (r2 = 0.48, p < 0.001). 







These results suggest that in this cohort of patients classic risk factors for CVD namely 
age, blood pressure, dyslipidaemia and obesity appear to play a role in AS and ED.  
There was little evidence to suggest inflammation or renal impairment played a 
significant independent role in AS and ED in this cohort. 
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3.1  Introduction 
 
Small vessel vasculitis (SVV) encompasses a group of inflammatory disorders 
characterised by leucocyte infiltration and necrosis of the small arteries. SVV includes 
the ANCA-associated systemic vasculitides (Wegener’s granulomatosis, microscopic 
polyangiitis and Churg-Strauss syndrome), vasculitis secondary to connective tissue 
disorders (such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)), 
Henoch-Schönlein purpura and cryoglobulinaemia. Symptomatic involvement may 
either affect a single organ or multiple organs; the kidney is affected in the majority of 
cases. Patients with SVV and renal involvement may present with kidney function 
ranging from normal through to renal failure requiring dialysis. The presence of blood 
and/or protein in the urine (an active urinary sediment) is highly suggestive of renal 
involvement, and this is confirmed by characteristic inflammatory changes on renal 
biopsy. SVV is often serious and sometimes fatal, and requires prompt recognition and 
treatment. When the kidney is involved, and if untreated, these patients may suffer an 
unremitting and aggressive renal attack that, if not fatal, results in ESRD and the 
necessity for long-term dialysis187. Fortunately, available treatments have proven to be 
successful in controlling SVV, increasing patient survival and turning this disease, in 
many cases, into a chronic relapsing condition.  
 
Cardiovascular disease (CVD) burden is significantly increased in patients with chronic 
inflammatory conditions. For example, the risk of a woman under the age of 45 with 
SLE (in the absence of renal involvement) developing atherosclerosis is 50 fold greater 
than that of an age-matched control188 and the mortality rate from cardiovascular disease 
is doubled in patients with RA189. 
 
In patients with SVV with renal involvement there are currently few data that relate to 
cardiovascular risk, and none that relate to cardiovascular mortality. However, in 
addition to traditional cardiovascular risk factors and the presence of CKD as a 
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cardiovascular risk factor, systemic inflammation may influence vascular function and 
thus increase cardiovascular risk in these patients. 
 
Vascular endothelial injury is the primary event in atherosclerosis92. In SVV, pro-
inflammatory cytokines depress endothelial function190, antineutrophil cytoplasmic 
antibody/neutrophil interact close to the vessel wall triggering endothelial damage191, 
and LDL oxidation promoted by the inflammatory microenvironment, leads to direct 
endothelial cell toxicity. Any or all of these factors may contribute to vascular 
endothelial damage192.  
 
 
There are few data that relate AS and ED to chronic inflammatory conditions. RA is 
associated with increased AS and this falls following treatment193. ED is a feature of 
vasculitis per se and occurs in both active and quiescent disease194. This latter study 
included patients with both larger vessel vasculitis and SVV, but the findings suggest 
that although SVV primarily affects small arteries, the impact of disease may actually be 
more widespread.  
 
 
Studying patients with active disease and those in remission, Booth et al. have 
demonstrated that ANCA-associated SVV is associated with increased arterial stiffness 
measured by PWV, and that stiffness correlates with the degree of active inflammation, 
assessed by CRP195. Additionally disease activity in ANCA-associated vasculitis has 
been associated with endothelial dysfunction, studied by forearm plethysmography, with 
an improvement in ED seen after successful induction of remission by 
immunosuppressive agents194, 196. 
 
It is likely, therefore, that as patient survival increases with SVV, late cardiovascular 
mortality will increase due to ongoing low-grade inflammation. It follows that, if 
inflammation is playing a significant role in long-term vascular disease in these patients, 
then early suppression of disease activity in chronic inflammatory disorders may reduce 
long-term vascular damage. Furthermore, those patients with SVV and renal 
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involvement are likely to have an even greater cardiovascular risk as a consequence of 
their superimposed renal impairment.  
 
3.1.1 Aims and hypotheses  
 
The aims of this study was to investigate the relationship between AS and ED to markers 
of renal impairment, metabolic dysfunction and inflammation in a cohort of patients 
with treated immune-mediated inflammatory renal disease who were classified as in 
‘remission’. Remission was defined as being on stable immunosuppression for a 
minimum of 1 year with no evidence of ongoing disease activity. 
 
Hypotheses: 
1. AS will worsen as renal function declines 
2. Renal function will predict AS independent of conventional risk factors such as age 
and BP 
3. This cohort of patients will have greater AS when compared to a matched group of 
patients with non-inflammatory CKD 
 
3.2 Study design 
3.2.1 Subjects 
Subjects were recruited from the renal outpatient clinic at the Royal Infirmary of 
Edinburgh. All patients had a diagnosis of immune-mediated inflammatory renal disease 
based on renal biopsy and were all classed as in remission and on maintenance therapy 
for  1 year. Remission was defined as the absence of disease activity attributable to 
active disease qualified by the need for ongoing stable maintenance immunosuppressive 
therapy.197 
 
Dr Pajaree Lilitkarntakul, working in our departement, obtained the data for the 
comparison group of CKD patients. These patients were classified as low-comorbidity 
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patients with no history of CVD, diabetes or inflammatory renal disease88.  They were 
recruited from the renal outpatient clinic at the Royal Infirmary of Edinburgh and 
categorised into 5 stages of CKD on the basis of the Kidney Disease Outcome Quality 
Initiative (K/DOQI) classification. 
 
 
3.2.2 Study protocol 
This was a prospective, cross-sectional study. Subjects refrained from alcohol for a 
minimum of 24 hours and caffeinated drinks, food and smoking for at least 12 hours 
prior to the study. Subjects were asked to not take their medications on the morning of 
the study. All studies were conducted in a quiet temperature-controlled room. Blood and 
urine samples as well as demographic data were taken and then subjects were rested in 
the supine position for 30 minutes. Following this, BP measurements, cAIx, PWV and 
FMD were performed as described in Chapter 2.  
 
3.2.3 Statistical Analysis 
Descriptive data are given as mean ± SD. Correlation coefficients were calculated using 
the Pearson method. Stepwise linear regression was used for multivariate analysis using 
computer software package SPSS Statistics. The variables used in the analysis can be 
seen in table 3.1. Significance was taken at a p value of < 0.05. 
 
3.3 Results 
3.3.1 Subject characteristics 
In total 22 subjects were enrolled into the study, 9 males 13 females. Of these, 14 had a 
diagnosis of ANCA-positive vasculitis, 7 had type IV lupus and 1 had crescentic IgA 
nephropathy. All had undergone immune modulation therapy and all were classified as 
in remission (no evidence of disease activity of at least 1 year).  The subject 
characteristics can be seen in table 3.1 
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3.3.2 Pulse wave velocity (PWV) 
PWV increased significantly with increasing age, SBP, triglycerides, urate and CRP. 
(Figure 3.1). Although there was no significant relation with creatinine or eGFR using 
the C&G equation, there was, a significant relation with eGFR when using the MDRD 
equation. 
 
Following multivariate analysis only age, triglycerides, and systolic BP predicted PWV. 
This remained constant whether C&G or MDRD equations were used to estimate GFR. 
3.3.3 Central Augmentation index (cAIx) 
cAIx increased significantly with increasing age (Figure 3.2) . This remained the case 
following multivariate analysis. 
 
3.3.4 Flow Mediated Dilatation (FMD) 
Only 19 of the 22 patients underwent FMD due to a breakdown of the ultrasound 
equipment. FMD fell significantly with increasing age and WHR and rose with 
increasing PCR. There was also a significant difference in FMD between male and 
female subjects with significantly great FMD seen in females. Following multivariate 





Table 3.1 Subject characteristics 
N=22 unless otherwise stated Mean (± SD) Min Max 
Diagnosis 
 ANCA vasculits N = 14 
 Type IV lupus N = 7 
 Crescentic IgA N=1 
   
Age, years  47 ± 16 20 70 
Gender (Male:Female) 9:13   
Creatinine, µmol/L 106 ± 58 43 261 
Creatinine clearance, mL/min/BSA 76 ± 40 24 179 
MDRD, mL/min/1.73 m2 76 ± 38 19 173 
Systolic blood pressure, mmHg 124 ± 18 101 163 
Diastolic blood pressure, mmHg 68 ± 7 57 84 
Mean arterial pressure, mmHg 87 ± 9 72 105 
Waist-hip ratio 0.93 ± 0.09 0.81 1.09 
Body mass index, kg/m2 29.5 ± 6.9 20.6 43.2 
Protein:creatinine ratio, mg/mmol 40 ± 77 4 315 
C-reactive protein, mg/L 5.8 ± 4.5 3 18 
Cholesterol, mmol/L 4.6 ± 1.0 2.7 6.6 
HDL, mmol/L 1.6 ± 0.4 0.9 2.7 
LDL, mmol/L 2.3 ± 0.9 1.1 4.5 
Triglycerides, mmol/L 1.6 ± 0.8 0.6 4.1 
Urate, µmol/L 0.38 ± 0.13 0.23 0.69 
Pulse wave velocity, m/sec 6.5 ± 2.2 4.2 14.4 
Augmentation index corrected to 
heart rate of 75bpm, % 
16.9 ± 10.6 1.0 32.5 












































































Figure 3.2 Augmentation index univariate analysis 
 







































































































3.3.5 Comparison with low co-morbidity CKD patients 
  
The current cohort of patients with inflammatory renal disease had the same age and 
sex distribution as the previous cohort of patients with non-inflammatory, low co-
morbidity renal disease. Renal function in the current group was greater than that of the 
CKD patients. The current cohort also had a improved lipid profile, with higher HDL 
and lower LDL cholesterol (Table 3.2). 
 
There was a non-significant difference in PWV between the inflammatory renal disease 
cohort and CKD cohort 6.5 m/s vs. 6.9 m/s. In the multivariate analysis combining both 
cohorts, age, MAP, urate, CRP were independent predictors of PWV. Multivariate 
analysis of cAIxfound only age and sex were independent predictors cAIx. Multivariate 
analysis for FMD found age, creatinine, cholesterol and inflammatory renal disease to 
be independent predictors of FMD. 
 
  
Table 3.2 Inflammatory renal disease vs. low co-morbidity CKD  
* denotes significance p <0.05 
 Study 1 (n=22) 
Mean (STD) 













76    (38) 53    (31) * 
Corrected GFR  
(ml/min) 
 
76    (40) 63    (35) * 
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68    (7) 74    (9) * 
MAP  
(mmHg) 














103  (14) 107  (9) 
WHR  
 




















































16.9 (10.6) 15.8 (11.6) 
PWV 
(m/s) 
6.5   (2.2) 6.9   (1.3) 
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3.4 Discussion 
I evaluated measurements of AS in a cohort of patients with known inflammatory renal 
disease who were classified as being in remission for at least 1 year. These inflammatory 
diseases are thought to confer a higher cardiovascular mortality. In SLE, for example, 
the risk of developing atherosclerosis is 50-fold greater than that of an age-matched 
control188. Previous work has shown that patients with chronic inflammatory 
rheumatological diseases such as SLE, rheumatoid and Behçet’s have increased PWV 
when compared to healthy controls193, 198, 199. To date, however, there has been little 
study of the impact of CVD in patients with chronic inflammatory renal disease, 
particularly the ANCA positive vasculitidies. 
 
In the current study, following multivariate analysis, age predicted AS as measured by 
PWV and cAIx. Triglycerides and systolic BP were also correlated with PWV. These 
findings broadly agree with previous work in other cohorts of patients. For example the 
cross-sectional analysis of the Framingham Heart Study by Mitchell et al. has previously 
shown that AS significantly increases with age. Following age adjustment, other 
important correlates included higher MAP, higher BMI, impaired glucose metabolism 
and abnormal lipids200. A further study by Aatola et al. examined PWV in 1691 white 
healthy adults in Finland. In this study sex, age, systolic BP, insulin and triglycerides 
were all independent predictors of PWV201.  Interestingly a recent study in patients with 
Behçet’s disease (an SVV that can also affect large vessels and commonly affects the 
mucous membranes) also found that triglycerides were an important predictor of 
PWV202.  Almost all the patients within the current study were treated with chronic 
prednisolone therapy (N=20). As prednisolone is known to increase both LDL and 
triglyceride levels203, based on our results and those mentioned, lipid lowering therapy 
should be considered particularly when commencing patients on steroids.  
 
In the current study there was no evidence of a relationship of PWV to renal function as 
measured by C&G or MDRD equations following multivariate analysis. This is in 
contrast to a previous larger low morbidity CKD cohort88. eGFR as measured by the 
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MDRD equation, however, was significantly correlated with PWV in the unvariate 
analysis. It is likely that, due to the wide distribution in renal function within the current 
study, there simply were not enough patients to show a significant correlation. 
 
CRP has previously been shown in some, but not all, studies to be an independent 
predictor of arterial stiffness in health204-206 and disease195.  Wilkinson’s team in 
Cambridge were one of the first to look at this in 2005. They found, in a cohort of over 
400 healthy volunteers, that PWV was significantly related to age, BMI, MAP, LDL 
cholesterol, triglycerides and CRP. There was no link with CRP and AIx204. 
Interestingly, a very similar study performed by Kullo et al. in a cohort of just over 200 
health subjects found CRP was not significantly associated with PWV but was with 
AIx206. Wilkinson’s team went on to examine AS in a group of 32 patients with ANCA-
associated vasculitis without renal involvement. They again found that CRP was 
positively correlated to PWV. Interestingly, this time a link between CRP and AIx was 
also found following multivariate analysis195. On the other hand a recent large study 
involving over 800 individuals with type II diabetes found CRP had no association with 
AS207.  In the current study there was a significant relationship between PWV and CRP 
in unvariate analysis. However, this disappeared following multivariate analysis. There 
was no association between CRP and AIx.  It may be that  CRP is only very weakly, if at 
all, associated with AS, if at all. However, it may be that sample size was too small to 
detect a significant correlation, particularly as most of these subjects had a CRP within 
the normal range because they were in remission (only 9/22 had a CRP above the lower 
limit of detection in the laboratory).  
 
In previous work from this department in 113 patients with CKD and low co-
morbidity88, CRP (again, largely in the normal range) was an independent predictor of 
PWV. When the results from these SVV patients in remission are added to this group, 
CRP remains an independent predictor of arterial stiffness (along with BP, age and 
urate) but having SVV in remission, as opposed to low co-morbidity CKD, was not an 
independent predictor of PWV in the combined cohort. When the two studies are 
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compared, the relationship between renal function and PWV is the same. It is likely, 
therefore, that low-grade inflammation is important but that the numbers in this study 
were insufficient to show a significant relationship. 
 
FMD measures endothelium-dependent dilatation of the artery in response to shear stress 
and, as such, can be used as a surrogate marker of endothelial function208. It has been 
shown to be adversely affected by classical CVD risk factors, with age, dyslipidaemia, 
diabetes and smoking being particularly strong determinants209.  In the current study 
FMD was adversely affected by increasing age and WHR, which, would be in keeping 
with previous studies209. The present study also found a significant difference in FMD 
between the sexes. This is in keeping with previous studies, which have shown that 
women have significantly greater FMD responses than men210, 211. This may, in large 
part, be a consequence of females having smaller diameter brachial arteries; therefore % 
change is often greater. There is also some evidence that oestradiol may play a role in 
this sex difference211.   
 
The positive relationship between FMD and proteinuria seen with this study was 
unexpected and is in contradiction to previous studies, which have shown a negative 
relationship. It is likely that small sample size and one major outlier may explain these 
current results 
 
In conclusion, the major determinants of arterial stiffness and endothelial dysfunction in 
this cohort of patients with inflammatory renal disease (in remission) appear, in large 
part, to be based on known significant cardiovascular risk factors, namely; age, BP, 
dyslipidaemia and obesity. Therefore good BP control, lipid control eg. with statins and 
lifestyle advice should be the mainstay of primary and secondary CVD prevention in this 
group. It is not possible to determine the role of low-grade inflammation from this study 
because the majority of the patients had CRPs at the lower limit of detection once in 
remission. However, there is a case for further investigation in this area, given that it 
appears to play a role in CKD patients in general. 
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Chapter 4: Investigation of arterial 
stiffness in active immune-














I have previously shown that, in patients with immune-mediated renal disease in 
remission, that markers of arterial stiffness and endothelial dysfunction are linked to 
classic cardiovascular risk factors: namely age, blood pressure, dyslipidaemia and 
obesity.  This current study followed a cohort of patients with a new diagnosis of 
immune-mediated inflammatory renal disease, following them for 1 year to examine 
what effect if any treatment has on arterial stiffness, hypothesising that as patients 
entered remission arterial stiffness would improve. 
 
Methods 
Aortic pulse wave velocity PWV was assessed in 10 patients over a 1-year period. 
Patients were studied at before treatment, and 2-weeks, 1-month, 3-months, 6-months 
and 12 months after treatment. These results were then compared to markers of disease 
activity and classic cardiovascular risk factors. 
 
Results 
All 10 patients achieved clinical remission of their disease by 1 year. Overall renal 
function improved significantly from baseline to 1-year as measured by eGFR (67±39 
vs. 81±39 ml/min p < 0.01) and PCR (367±333 vs. 48±63 mg/mmol p <0.05). There was 
also a significant fall in PWV over this period (6.1±1.1 m/s vs 5.7±1.3 m/s, p < 0.01). 
This fall in PWV was correlated to improvement in renal function on both unvariate and 
multivariate analysis. PWV did not correlated with any other measures.  
 
Conclusion 
PWV falls following treatment of acute immune-mediated renal disease and its 





In chapter 3 I looked at cardiovascular risk factors in a cohort of patients with immune-
mediated renal disease who were currently in remission from the disease. In this study I 
further examined that risk in a cohort of newly diagnosed patients, following them for 1 
year to examine what impact, if any, treatment and subsequent disease remission had on 
markers of AS. 
 
4.1.1 Aims and hypotheses  
The aims of this study was to investigate the relationship between AS and markers of 
renal impairment, metabolic dysfunction and inflammation in a cohort of patients with 
newly diagnosed ‘active’ immune-mediated inflammatory renal disease 
 
Hypotheses: 
1. AS would improve as renal function improves. 
2. AS would improve as markers of inflammation fall. 
 
4.2 Study design 
4.2.1 Subjects 
Subjects were recruited from the renal ward of the Royal Infirmary of Edinburgh. All 
patients had a diagnosis of an inflammatory autoimmune disease on renal biopsy and all 
were commenced on immunomodulatory therapy. 
 
4.2.2 Study protocol 
This was a longitudinal study following patients for 1 year. Subjects were studied at 
before treatment, and after 2 weeks, 1 month, 3 months, 6 months and 12 months of 
treatment. Subjects refrained from alcohol for a minimum of at least 24 hours and 
caffeinated drinks, food and smoking for at least 12 hours prior to the study. Subjects 
were asked to not take their medications on the morning of the study. All studies were 
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conducted in a quiet temperature-controlled room. Blood and urine samples as well as 
demographic data were taken and then subjects were rested in the supine position for 30 
minutes. Following this, measurements of BP and AS were performed as described in 
Chapter 2. 
 
4.2.3 Statistical Analysis 
Descriptive data are given as mean ± SD. Correlation coefficients were calculated using 
the Pearson method. Stepwise linear regression was used for multivariate analysis. 
Significance was taken at a p value of < 0.05. 
 
4.3 Results 
4.3.1 Subject characteristics 
10 subjects, 5 males and 5 females, were enrolled and followed up over a 1-year period.  
Of these 5 had a diagnosis of type III or IV lupus nephritis, 4 ANCA + vasculitis and 1 
crescentic IgA nephropathy. A summary of individual diagnoses and treatment regimens 














Table 4.1 Diagnosis and treatment regimens of study patients  















































































































LN: Lupus Nephritis, PEX: Plasma Exchange, CYC: Cyclophosphamide, MMF: Mycophenolate Mofetil  
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Table 4.2 Baseline characteristics 
N= 10  Mean (± SD) Min Max 
Age, years 40 ± 16 23 61 
Gender (Male:Female) 5:5   
Creatinine, µmol/L 147 ± 189 60 389 
Creatinine clearance, mL/min/BSA 67 ± 39 10 120 
MDRD, mL/min/1.73 m2 72 ± 40 11 113 
Systolic blood pressure, mmHg 140 ± 20 102 167 
Diastolic blood pressure, mmHg 77 ± 13 56 102 
Mean arterial pressure, mmHg 98 ± 14 71 120 
Waist-hip ratio 0.95 ± 0.09 0.79 1.11 
Body mass index, kg/m2 27.9 ± 4.4 21.3 34.2 
Protein:creatinine ratio, mg/mmol 367 ± 333 36 976 
C-reactive protein, mg/L 24 ± 18 3 54 
Cholesterol, mmol/L 5.5 ± 1.7 2.6 7.9 
HDL, mmol/L 1.1 ± 0.3 0.7 1.5 
LDL, mmol/L 3.4 ± 1.5 1.3 5.6 
Triglycerides, mmol/L 2.1 ± 0.9 0.9 3.7 
Urate, µmol/L 0.36 ± 0.12 0.22 0.59 
Pulse wave velocity, m/sec  6.1 ± 2.2 4.2 7.5 
Augmentation index corrected to heart 
rate of 75bpm, % 
20 ± 17 -15 45 
 
4.3.2 Renal function 
Over the 12-month period 9 out of the 10 patients had improvements in renal function.  
Overall, there was a significant increase in renal function as measure by the C&G 
equation  (67±39 vs. 81±39 ml/min p < 0.01). There was a trend to increasing eGFR 
after the 2-week time point but this did not reach significance level.  Proteinuria as 
measured by PCR also fell significantly by 12 months (367±333 vs. 48±63 mg/mmol p 
<0.05) (Fig 4.1). 
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Figure 4.1 Effect of treatment on renal function 
  
 
4.3.3 Pulse wave velocity (PWV) 
PWV was significantly lower at 12 months compared to baseline (6.1±1.1 m/s vs. 
5.7±1.3 m/s, p < 0.01) (Fig 4.2A). There was a trend to reducing PWV after the 2-week 
time point but this did not reach significance (Fig 4.2B). 
 
Age and CRP were independent predictors of PWV at baseline, before induction 
treatment. At 12 months, no one variable independently predicted the absolute PWV 
value. Absolute PWV at baseline and at 12 months was significantly correlated with 
renal function in univariate analysis but this was not an independent predictor of PWV at 
either time point. However, in multivariate analysis, change in PWV over 12 months 





























































correlated with change in blood pressure, CRP, ESR, lipids, PCR or weight. There is an 
identical relationship when PWV is plotted against eGFR at both baseline and 12 
months, suggesting that the effect of treatment on PWV is largely due to the effect on 
eGFR, with 9/10 patients having an improvement in GFR (67.2±39.2 vs 80.6±38.9 
ml/min) (Fig 4.3) 
 




































In the current study, renal function improved notably following treatment with a 
significant increase in eGFR and fall in proteinuria. All patients were classed as in 
remission by 12 months.  PWV also significantly fell from baseline to 12 months with a 
trend to reducing PWV after the 2-week time point suggesting that the effect of 
treatment on arterial stiffness begins relatively rapidly though, with such a small sample 
size, this was not significant. 
 
In comparison to the previous chapter, where classical cardiovascular risk factors such 
as age, BP and lipids were correlated to PWV, no such correlations were found when the 
patients were in remission, though the numbers studied were small. Inflammation, 
measured by CRP, did independently predict AS as measured by PWV at diagnosis 
(before treatment), as did age but by 12 months, CRP had normalised and no significant 
relationship between inflammation and arterial stiffness was found. Strikingly, the only 
correlation to PWV in this current cohort of patients was renal function in that the 
change in PWV from diagnosis (baseline) to remission (12 months) was only predicted 
by change in creatinine. Indeed the overlapping trend lines seen in figure 4.3 suggest 
that the improvement in PWV is linked to improvement in renal function, though it is 
not clear if this is a direct consequence of improved renal function.  
 
This is the first study to examine PWV in a cohort of adult patients with immune-
mediated inflammatory renal disease and follow them through the first year of treatment. 
A previous study by Booth et al., the only other study to examine PWV in a cohort of 
patients with ANCA-associated vasculitis, showed that PWV was increased in active 
disease compared to a matched group of patients in disease remission, which would be 
in keeping with my current results.  They also showed that PWV was linked to CRP and 
BP. This study, however, excluded subjects with renal impairment as defined as a 
creatinine clearance of <50 ml/min and as such found no link with renal function195.  
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Only one other study has examined PWV in AKI, a cohort with acute post-streptococcal 
glomerulonephritis (APSGN). APSGN is an immune-mediated disease occurring after 
streptococcal infection. Its cause is unclear, but 2 possibilities have been postulated; one 
that circulating immune complexes form with streptococcal antigenic components and 
these subsequently become deposited within the glomerulus with associated complement 
activation; the other is that of molecular mimicry212. It is in effect similar to the 
conditions studied within the current study, though its management is normally only 
supportive and complete recovery is seen in most patients. Yu et al. examined PWV in a 
group of 16 children with APSGN comparing them to a similar cohort of children with 
acute pyelonephritis (APN) and healthy controls. Subjects were followed up for an 
average of 2 years. They found that PWV was significantly elevated in the APSGN 
group compared to the APN and healthy control groups. As renal function improved 
PWV in the ASPGN group fell to normal levels213. Unfortunately, this study did not 
examine other markers of disease so it is not clear if inflammation or other 
cardiovascular markers had any impact on improvement in PWV. 
 
In conclusion I have shown in a small cohort of patients with acute immune-mediated 
renal disease that improvements in renal function confer significant improvements in 
PWV. Failure to achieve significant improvements in renal function may lead to 
increased risk of CVD. Further work is required in this field particularly examining the 
effect that AKI has on arterial stiffness and endothelial function.  
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Chapter 5: Investigation of 
functional ETB receptor 
antagonism after bosentan and 

























ET-1 is implicated in the development of hypertension and a role for ETRAs in the 
management of hypertension is emerging. ETRAs are classified as selective or mixed 
depending on their degree of ETA:ETB receptor blockade. As yet, there are no 
comparative studies in humans that measure biochemical and functional ETB blockade 
achieved by currently licensed ETRAs. I therefore investigated the effects of bosentan, a 
mixed ETRA, and sitaxsentan, an ETA selective ETRA, on plasma ET-1 concentrations 
and ETB-mediated vasodilatation to ET-3. 
 
Methods 
In a randomized, double-blind, 3-way cross-over study, 10 healthy subjects received 7 
days of placebo, bosentan 250mg and sitaxsentan 100mg daily. Plasma ET-1 
concentrations were measured at baseline and 3h on day 1 and predose on day 7. 
Subjects also underwent forearm blood flow (FBF) measurements on day 7 of each 
period with brachial artery infusion of ET-3 (60pmol/min for 5min). 
 
Results 
Bosentan, but not placebo or sitaxsentan, significantly increased plasma ET-1 
concentrations at day 7 (+0.70±0.20pg/ml; P<0.005). Maximal ET-3 mediated 
vasodilatation was seen at 2min following placebo (30±6%) and sitaxsentan (21±11%), 
however this was abolished by bosentan, with a reduction in FBF of 8±3% (P<0.01 vs. 
placebo and sitaxsentan) 
 
Bosentan but not sitaxsentan increases circulating plasma ET-1 levels and abolishes 
acute ET-3 mediated vasodilatation, confirming that the mixed ETA/B antagonist 
bosentan, but not the selective ETA antagonist, sitaxsentan, causes functional ETB 




ET-1 acts via two specific receptors, the ETA and the ETB receptors214. Within the 
vasculature ETA receptors are expressed predominantly on vascular smooth muscle cells 
(VSMC), cardiomyoctes and fibroblasts110. Their activation results in sustained 
vasoconstriction, cell proliferation and fibroblast activation110. In contrast, ETB receptors 
are predominantly expressed on endothelial cells and mediate vasodilatation primarily 
through NO215. The role of the ETB receptor however is more complex, as they are also 
present on VSMC and fibroblasts where they too contribute to vasoconstriction, 
proliferation and fibrosis119, 216, 217. In addition, ETB receptors, particularly in the 
pulmonary circulation, act as the primary clearance mechanism for circulating ET-1218.  
 
Despite the hypothesized benefits of the unblocked ETB receptor, which include 
preserved endothelial dependent NO mediated vasodilatation, ET-1 clearance and 
natriuresis and diuresis, to date no clinically relevant differences have been 
demonstrated in vivo between selective ETA and mixed ETA/B ETRAs.  
 
I therefore examined biochemical and functional markers of ETB receptor antagonism in 
vivo in healthy subjects following 7-day oral dosing with either the selective ETA 
antagonist sitaxsentan or the mixed ETA/B antagonist bosentan at clinically licensed 
doses. I hypothesized that bosentan, but not sitaxsentan, would affect biomarkers for 
ETB receptor function, specifically to increase plasma ET-1 and reduce ET-3 mediated 
vasodilatation through functional ETB receptor blockade. 
 
5.2 Study Design 
5.2.1 Subjects 
The study was undertaken in 10 healthy male volunteers recruited from the local 
community and had the approval of the local research ethics committee. Written 
informed consent was obtained from each subject before entry into the study.  All 
 93
subjects were allocated to a randomized treatment sequence of placebo, sitaxsentan and 
bosentan.  
 
5.2.2 Study protocol 
This was a three-way, randomized, double-blind placebo-controlled cross-over trial. The 
study consisted of three 7-day treatment periods with placebo, sitaxsentan 100mg or 
bosentan 125mg twice daily in a randomized order (see methods for justification of 
dose). As the bosentan arm had twice daily dosing, to maintain blinding, placebo was 
given as a twice-daily tablet and during the sitaxsentan phase a matched placebo was 
given in the evening. There was a minimum 14-day washout between periods. On day 1 
of each study period subjects were required to attend the research centre fasted at 0900h. 
Following baseline blood sampling the study drug was administered. A further blood 
sample was then taken at 3 hours after dosing. Subjects were then allowed home and 
continued to take the study drug for 7 days. (Figure 5.1a) 
 
On day 7 patients attended the research centre at 0900h. Following baseline BP and 
plasma ET-1 sampling, the last dose of study drug was taken. Patients then rested for 3 
hours prior to forearm blood flow measurements at peak plasma concentrations of the 
study drugs162, 219. Following left brachial arterial cannulation saline was infused for 30 
minutes during which two measurements of FBF were made (at -20 and -10 minutes). 
ET-3 was then infused via the brachial artery at 60 pmol/min for 5 minutes, followed by 
physiological saline for 60 minutes. Forearm blood flow was recorded from 3 minutes 
before to 10 minutes after the ET-3 infusion was begun. Thereafter, measurements were 
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or placebo as per randomisation
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5.2.3 Statistical Analysis 
Based on previous data161, it was calculated that for 10 subjects  there was an  80% 
probability that the study will detect a treatment difference at a two sided 5% 
significance level, if the true difference in the ratio of flow between the infused and non-
infused arms between the treatments is 14%. This was based on the assumption that the 
standard deviation of the difference in the response variables was 10%. I expected to see 
a difference between the bosentan arm vs. placebo and sitaxsentan arms of 
approximately 20%186. 
 
The co-primary end points were change from baseline of plasma ET-1 and maximal 
forearm vasodilatation to ET-3. Three comparisons of interest were pre-identified: 
placebo versus sitaxsentan, placebo versus bosentan, and sitaxsentan versus bosentan.  
 
5.3  Results 
Ten healthy men with a mean age of 36±16 years (range 20-66 years) were recruited and 
completed all 3 phases of the study. Three of the ten subjects were cigarette smokers. 
Overall subjects had a mean SBP of 121±11 and diastolic BP of 68±7 mmHg. Mean 
body mass index was 23±2 kg/m2. No adverse effects of treatment were reported.  
 
5.3.1 Plasma ET-1 
Baseline plasma ET-1 concentrations were not significantly different between study 
periods (placebo; 3.44±0.27 pg/ml, sitaxsentan 3.42±0.21 pg/ml, bosentan 2.92±0.22 
pg/ml). Following pre-treatment with either placebo or sitaxsentan there was no 
significant change in plasma ET-1 concentrations from baseline to 3 hours or on day 7. 
Following pre-treatment with bosentan, however, there was a trend to a rise in plasma 
ET-1 concentrations at 3 hours (+0.51±0.26pg/ml P=0.07) and a significant increase at 






Figure 5.2 Plasma ET-1 concentrations  






5.3.2 FBF study 
Baseline BP, heart rate and forearm blood flow were similar during the study days and 
there was no significant difference in basal FBF between infused and non-infused arms 
(Table 5.1). BP and heart rate, and FBF in the non-infused arm, did not significantly 
change after infusion of ET-3, confirming that the effects of ET-3 were confined to the 





Table 5.1 Forearm blood flow haemodynamic data  
Values are mean ± SEM 
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2.0 ± 0.2 
 
2.2 ± 0.2 
 
2.6 ± 0.4 
 
 
2.4 ± 0.4 
 
2.7 ± 0.5 
 
2.7 ± 0.3 
 
 
2.1 ± 0.2 
 
2.4 ± 0.2 
 
2.4 ± 0.3 
 98
Following pre-treatment with placebo, intra-arterial infusion of ET-3 caused significant 
local vasodilatation with a maximal increase in FBF of 30±6% at 2 min (P<0.01 vs. 
baseline). This dilatation persisted for 5 minutes. Similar results were seen following 
pre-treatment with sitaxsentan, with ET-3 causing a peak increase in FBF of 21±11% at 
2 min (P=0.44 vs. placebo). Pre-treatment with bosentan, however, abolished ET-3 
induced vasodilatation, and was associated with a reduction of FBF at 2 min of  8±3% 
(P<0.01 vs. placebo and sitaxsentan)  (Figures 5.4 & 5.5). 
 
Figure 5.3 Forearm blood flow (FBF) during the whole study (65min) 
Shaded area indicates period of ET-3 infusion (0.16g/min). Values are given as 
































Figure 5.4 FBF expanded to show 5 min period of ET-3 infusion.  
Values are given as the ratio between infused and non-infused arm (%) ± SEM. 
* P <0.005 bosentan vs. placebo; + P<0.05 bosentan vs. sitaxsentan (ANOVA 
plus Bonferroni correction for significance at specific time points). 
 
5.4 Discussion 
This study has demonstrated that 7-days treatment with bosentan, a mixed ETA/B 
receptor antagonist, increases plasma ET-1 concentrations and abolishes acute ET-3 
mediated vasodilatation. Neither of these effects was seen with the selective ETA 
receptor antagonist sitaxsentan, confirming that bosentan, but not sitaxsentan, causes 
functional ETB blockade, at the standard clinically licensed doses, in healthy humans. 

























biochemical and functional effects in humans, which may be relevant to the benefits and 
harms of these drugs.  
 
The ETB receptor has an important role in clearing circulating ET-1. Thus, blockade of 
this receptor would be expected to cause a rise in plasma ET-1218. Indeed ET-1 
concentrations are elevated in animal ETB receptor knockout models220, 221. Furthermore, 
studies with both selective ETB132, 222 and mixed ETA/B receptor antagonists132, 223 in 
humans have shown that plasma ET-1 concentrations rise following their administration. 
In contrast, the highly selective ETA receptor antagonists BQ-123, sitaxsentan and 
ZD4054 (ZD4054 has no measurable affinity for the ETB receptor) do not increase ET-1 
concentrations132, 224-226. In the current study I have shown that plasma ET-1 
concentrations increase significantly following bosentan, but not sitaxsentan, therapy in 
keeping with the important clearance role of the ETB receptor. Accumulation of ET-1 
may, theoretically, compete with the antagonist at the ETA receptor making the agent 
less effective.  
 
I use FBF response to ET-3 was used as a functional marker of ETB activation following 
7-day ETRA dosing. Activation of ETB receptors with either ET-3161 or sarafotoxin 
S6c186 (another selective ETB agonist) cause brief vasodilatation which is likely to be, in 
large part related to NO generation in humans215. Importantly the transient vasodilatation 
is abolished by BQ-788 (a highly selective ETB receptor antagonist), confirming that this 
is likely to be an ETB receptor-dependent effect186, consistent with a multitude of studies 
in animals110.  In keeping with previous studies161, I found that intra-arterial ET-3 
infusion caused significant early forearm vasodilatation, during placebo treatment. A 
similar response was seen during treatment with sitaxsentan signifying that endothelial 
ETB receptors were still functionally active in this group. The abolition of ET-3 induced 
vasodilatation during treatment with bosentan, however, demonstrates functional ETB 
receptor blockade following this treatment. Interestingly, in the current study, following 
vasodilatation there was no significant vasoconstriction seen in any of the treatment 
arms. This is contrary to previous studies using ET-3161 and sarafotoxin S6c186 and it is 
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not clear why this should be. Importantly, however, within the forearm it appears that 
vasoconstriction is likely to be primarily mediated via the ETA receptor in health186 and 
as such provides no further information on the function of the ETB receptor. 
 
To date, ETRA selectivity has been based solely on in vitro competitive receptor assays. 
However, different assays can produce greatly varying results depending on cell types 
and concentrations of drug used. For example the ETA:ETB ratios reported for 
ambrisentan vary widely, from 29:1 in rat aorta227 to 4000:1 in human myocardial 
membranes228. Furthermore, it is possible that “selective” ETA receptor antagonists may 
cause functional ETB receptor blockade if given at sufficiently high doses.  Indeed, there 
are a number of  “selective” ETA antagonists that have been shown to increase 
circulating plasma ET-1 concentrations229-231, suggesting that these compounds, at the 
doses used, may not be acting as functionally selective antagonists, with significant 
degrees of ETB receptor blockade. These effects may be relevant to clinical outcomes. 
For example, I have shown that 7-day treatment with a mixed ETRA abolishes ETB 
dependent vasodilatation, a pathway that may well have therapeutic benefit in a number 
of conditions including hypertension. It would also suggest that other beneficial actions 
of the ETB receptor in hypertension such as natriuresis and diuresis may also be lost and 
would be in keeping with previous acute studies which shown that concomitant ETB 
blockade impairs natriuresis and renal blood flow132, 232. Conversely, mixed ETA/B 
receptor antagonism may be required to block the secretagogue effect of ET-1 on 
aldosterone within the zona glomerulosa233.  It is therefore important to be able to clearly 
classify ETRAs as selective or mixed based on in vivo rather than in vitro models prior 








Chapter 6: The effects of oral 
acute and chronic selective ETA 
receptor antagonism on systemic 




































It has previously been shown that acute intravenous ETA but not acute ETA/B antagonism 
lowers systemic BP and renal blood flow in patients with CKD. These effects are similar 
to those seen with blockade of the RAAS, and would suggest a degree of renal 
protection. I therefore investigated the effects of an oral ETA antagonist on acute 
systemic and renal haemodynamics in a cohort of CKD patients. 
 
Methods 
In a randomized, double-blind, 3-way cross-over study, 13 patients were randomised to 
receive placebo, sitaxsentan 100mg or nifedipine LA 30mg given once daily for a period 
of 6 weeks. On day 1 and end off week 6 for each study block, patients underwent a 
renal clearance study where systemic and renal haemodynamics were measured.  
 
Results 
Sitaxsentan produced a significant drop in systemic vascular resistance but not BP. 
Sitaxsentan had no effect on renal blood flow or renal vascular resistance. However, 
EFF fell significantly by 6 weeks (20.8 ± 1.0 to 16.6 ± 07; p<0.01). There was an 
associated fall in GFR over the same 6-week period (57 ± 8 to 48 ± 8; p <0.05). Sodium 
handling by the kidney was not affected. 
 
Conclusion 
The significant drop in EFF and GFR following sitaxsentan therapy suggests that it 
cause preferential dilation of the afferent arterioles within the kidney. This suggests a 








6.1  Introduction 
Goddard et al.132 have previously shown that acute ETA but not acute ETA/B antagonism 
lowers systemic BP and renal blood flow in patients with CKD. These effects were 
consistent with a renoprotective action. The aim of the current study was to evaluate 
whether Sitaxsentan, a selective ETA antagonist that has been shown to have no 
functional ETB blockade in vivo (see chapter 5), would have similar effects on systemic 
and renal haemodynamics in a CKD population.  
 
6.2  Study design 
6.2.1  Subjects 
We enrolled 13 subjects with stable CKD stages I to IV22 and significant proteinuria 
(>300 mg/day). Subjects were already on maximally tolerated ACE inhibitor (ACE-I) 
and/or angiotensin receptor blocker (ARB) therapy to control BP and proteinuria. All 
medications were unchanged over the 3 months preceding the study. 
 
To enhance homogenicity and avoid other influences on vascular reactivity, patients 
with vasculitis or other systemic inflammatory renal disease, polycystic kidney disease 
or obstructive uropathy were excluded. Furthermore patients with significant co-
morbidities, including diabetes mellitus, heart or lung disease, liver disease and 
peripheral vascular disease were excluded. As sitaxsentan is teratogenic women of 
childbearing potential were also excluded from taking part in the study. 
 
6.2.2  Study protocol 
This was a three-way, randomised placebo-controlled study. The study consisted of three 
6-week treatment phases with placebo, sitaxsentan 100mg or nifedipine LA 30mg given 
once daily in addition to their regular medications. Each phase was separated by a 
minimum 14-day washout period.  
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Patients underwent standard clearance studies (see chapter 2) on day 1 and at the end of 
week 6 for each phase. Bioimpedance and BP measurements were taken every 15 
minutes. Urine and blood samples were taken hourly. Study drug (sitaxsentan, nifedipine 
or placebo) was given following baseline measurements after a 2-hour period to allow 
equilibration of water, para-aminohippurate acid and Inutest. Following study drug 
ingestion measurements were taken for a total of 4-hours (Fig 6.1) 
 











PAH: Para-aminohippurate acid 
 
6.3 Results 
Thirteen patients were enrolled in the study with all completing the 3 phases of the 
study. Baseline characteristics can be seen in table 6.1. 
 
 










End of study 
16:00 
 Bioimpedance and BP measurements taken 
every 15 minutes 










Values are given as mean of 3 baseline pre-treatment periods ± SD. GFR: 
glomerular filtration rate; PCR: protein:creatinine ratio; ACE: angiotensin 
converting enzyme; ARB: angiotensin receptor blocker. 
 






















Body mass index, kg/m2 
 















127 ± 10 
 
80 ± 8 
 









Serum potassium, mmol/l 
 
152 ± 67 
 
55 ± 26 
 
132 ± 16 
 





4.4 ± 1.0 
 
 














2.01 ± 1.6 
 










ACE inhibitor + ARB 
 



























6.3.1  Systemic haemodynamics  
After placebo correction there was a non-significant trend for BP reduction over the 4-
hour clearance study period with both sitaxsentan and nifedipine (Figure 6.2). There 
was, however, a significant drop in SVRI of almost 20% in both nifedipine and 
sitaxsentan by the end of the study period (Figure 6.3) 
 
6.3.2  Renal blood flow 
There was no change in ERBF from day 0 to week 6 with placebo, sitaxsentan or 
nifedipine. GFR was comparable at day 0 and week 6 with placebo and nifedipine, 
however, sitaxsentan produced a substantial fall in GFR by week 6. Similarly EFF was 
unchanged between day 0 and week 6 with both placebo and nifedipine, however, EFF 
was lower with sitaxsentan. This was a consistent finding with 12 out of 13 subjects 
demonstrating a fall in EFF. 10 subjects had a EFF of >20% at baseline. These subjects 
showed a fall of >2% (range 2.1 – 8.9%) after 6 weeks’ sitaxsentan treatment. The 3 
subjects with a EFF <20% at baseline showed less impressive reductions in EFF 
following sitaxsentan dosing. All changes in renal haemodynamics had returned to 
baseline before starting the next phase of the study (minimum 2 weeks). 
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6.3.3  Natriuresis 
There was no significant difference in sodium excretion between sitaxsentan and 
placebo over the 4-hour study period (Figure 6.6) 
 
Figure 6.2 Mean Arterial Pressure during clearance studies 
Data presented are placebo corrected % change from baseline and area under the curve. 
* p <0.05 vs. placebo 
































































Figure 6.3 Systemic Vascular Resistance Index during clearance studies 
Data presented are placebo corrected % change from baseline and area under 
the curve. * p <0.05 , + p <0.01 vs. placebo 
 






























































Table 6.2 Renal data from clearance studies at baseline and week 6  
Values are given as pre-dosing baseline  SEM. GFR: glomerular filtration rate; 
ERBF: effective renal blood flow; ERVR: effective renal vascular resistance; 
EFF: effective filtration fraction. * p < 0.01 and + p < 0.05 for sitaxsentan at week 

























56 ± 7 
 
54 ± 8 
 
57 ± 8 
 
48 ± 8+ 
 
59 ± 8 
 





533 ± 66 
 
552 ± 65 
 
511 ± 63 
 
543 ± 73 
 
562 ± 82 
 





230 ± 52 
 
206 ± 39 
 
236 ± 44 
 
232 ± 48 
 
248 ± 58 
 






19.1 ± 1.1 
 
17.9 ± 1.3 
 
20.8 ± 1.0 
 
16.6 ± 0.7* 
 
20.3 ± 1.1 
 
20.5 ± 1.4 
Figure 6.4 Effect of placebo, sitaxsentan and nifedipine LA 30mg on EFF.  


































Individual subject data are presented, as well as the mean ± SEM at baseline 
and 6 weeks. 
 
 
Figure 6.5 Effect of placebo, sitaxsentan on urinary sodium excretion 
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This is the first study to examine the acute effects of an oral selective ETA antagonist on 
systemic and renal haemodynamics in a cohort of patients with proteinuric CKD.  
 
While there was no statistical change in BP over the 4-hour study period with 
sitaxsentan or nifedipine there was a clear trend towards a fall. There was however a 
significant drop in SVRI which would be in keeping with systemic vasodilatation and 
has been previously reported with both nifedipine234 and sitaxsentan151. These findings 
suggests that ET-1 contributes to the maintenance of vascular tone in patients with CKD 
via the ETA receptor, and would be in keeping with previous studies 132, 235, 236. 
Interestingly, while the drop in SVRI was only observed acutely with nifedipine, 
sitaxsentan continued to have a significant effect on SVRI at 6 weeks.  
 
In this study sitaxsentan had no effect on renal blood flow or renal vascular resistance. 
However, as in previous studies132, 235, there was a very consistent fall in filtration 
fraction (−4%). This suggests that ET-1 induces an ETA receptor-mediated preferential 
efferent arteriolar constriction. These effects are analogous to, and occur in addition to, 
those seen with RAAS blockade. This postulated reduction in efferent arteriolar tone 
with ETA receptor antagonism should reduce glomerular perfusion pressure. This will 
result in a reduction in proteinuria with an associated short-term fall in GFR. Consistent 
with this proposed effect, we observed a significant fall in GFR (−9 mL/min) after 6 
weeks of sitaxsentan treatment. In patients already prescribed blockers of the RAAS, 
these effects, despite an initial fall in GFR, should correlate with longer-term slowing of 
the rate of CKD progression. 
 
Surprisingly, given the evidence for ETB receptor–mediated natriuresis126, no changes in 
sodium excretion or fractional excretion were observed in the present study and is in 
agreement with Goddard et al.132. Importantly, however, during ETA receptor blockade, 
despite systemic vasodilatation and reduction in EFF, sodium retention did not occur, 
which is important if these drugs are to be prescribed safely to patients with CRF. 
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In conclusion, I have shown that the oral ETA receptor antagonist sitaxsentan leads to 
system vasodilatation while reducing EFF patients with CKD. In addition, chronic 
dosing with sitaxsentan leads to a drop in GFR, which presumably relates to a fall in 
glomerular pressures. There was no evidence of acute sodium retention following oral 
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Proteinuria, hypertension and AS are associated with progression of CKD and are also 
independent risk factors for CVD. Acute blockade of the ETA receptor in patients with 
proteinuric renal disease has previously been show to reduced proteinuria and improve 
BP and AS. This study was designed to investigate if these effects would be seen with 
chronic dosing of an oral ETA antagonist 
 
Methods 
In a randomized, double-blind, 3-way cross-over study, 27 patients with proteinuric 
CKD on maximal tolerated RAAS blockade received 6 weeks of placebo, 100mg once 
daily sitaxsentan, and 30mg once daily of long acting nifedipine. Twenty-four-hour 
proteinuria, PCR, 24-hour ambulatory BP and PWV were measured at baseline and 
week 6 of each treatment.   
 
Results 
Sitaxsentan reduced 24-hour proteinuria (-0.61 ± 0.1 g/d: P < 0.0001), PCR (-42 ± 8 
mg/mmol; P < 0.0001), MAP (-3.7 ± 1.0 mm Hg; P = 0.004), and PWV (-0.41 ± 0.16 
m/s; P = 0.003). Although nifedipine matched BP and PWV when compared to 
sitaxsentan, it had no significant effect on proteinuria.  
 
Conclusion 
These results suggest that chronic dosing with a selective ETA antagonist may provide 









Sitaxsentan a selective ETA antagonist has previously been shown to have acute effects 
within the kidney that are similar to ACE-I, most notably reduction in EFF (See Chapter 
6). The aim of this study was to evaluate what effect chronic oral dosing of sitaxsentan 
would have in a cohort of patients with non-diabetic proteinuric kidney disease, who 
were already on maximal tolerated ACE-I +/- ARB therapy. We hypothesised that 
chronic dosing of sitaxsentan would have favourable effects on proteinuria, systemic BP 
and AS. 
 
7.2 Study design 
7.2.1 Subjects 
27 patients with stable CD stages I to IV22 and significant proteinuria (>300 mg/day) 
were enrolled. Subjects were already on maximally tolerated ACE inhibitor and/or ARB 
therapy to control BP and proteinuria. All medications were unchanged over the 3 
months preceding the study. 
 
To enhance homogeneity and avoid other influences on vascular reactivity, patients with 
vasculitis or other systemic inflammatory renal disease, polycystic kidney disease or 
obstructive uropathy were excluded. Furthermore patients with significant co-
morbidities, including diabetes mellitus, heart or lung disease, liver disease and 
peripheral vascular disease were excluded. As sitaxsentan is teratogenic, women of 
childbearing potential were also excluded from taking part in the study. 
 
7.2.2 Study protocol 
This was a three-way, randomised placebo-controlled study. The study consisted of three 
6-week treatment phases with placebo, sitaxsentan 100mg or nifedipine LA 30mg given 
once daily in addition to their regular medications. Each phase was separated by a 
minimum 14-day washout period. 
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Proteinuria, BP and AS were assessed at baseline, week 3 and week 6 of each study 
period (Fig 7.1). Proteinuria was assessed using both the mean 24-hour protein excretion 
and the mean PCR of 3 consecutive 24-hour urine collections. Ambulatory BP was 
measured at the brachial artery with measurements taken every 30 minutes for a 24-hour 
period. Measurements of AS (PWV and augmentation index) were measured as 
described in Chapter 2. Safety data: “office BP”, weight, haemoglobin, haematocrit, 
liver enzymes, serum potassium and adverse effects were recorded at baseline and at 
weeks 1, 2, 3, 4, 5 and 6.  
 
 






7.2.3 Statistical analysis 
The primary end point of this study was change in proteinuria at 6 weeks. Secondary end 
points were change in systemic BP and AS. Using data from a previous study it was 
calculated that a minimum of 24 patients would be required for the study to have 80% 
power to detect a reduction in proteinuria of 0.7g/d237. 
 
Baseline 
24h Urine collection x3 
24h blood pressure 
monitoring 
Arterial stiffness 
Safety data  
Week 3 
24h Urine collection x3 
24h blood pressure 
monitoring 
Arterial stiffness  
Safety data 
Week 6 
24h Urine collection x3 
24h blood pressure 
monitoring 
Arterial stiffness  
Safety data 
6 week study period 
Week 1 & 2 
Safety data  
Week 4 & 5 
Safety data  
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7.3  Results 
Of the 27 patients recruited, all completed all the 3 phases of the study. Baseline 
characteristics can be seen in table 7.1 
 
Table 7.1 Baseline characteristics 
Values are given as mean of 3 baseline pre-treatment periods ± SD. GFR: 
glomerular filtration rate; PCR: protein:creatinine ratio; ACE: angiotensin 


























Body mass index, kg/m2 
 















125 ± 12 
 
78 ± 7 
 









Serum potassium, mmol/l 
 
153 ± 75 
 
54 ± 26 
 
136 ± 18 
 





4.6 ± 0.8 
 











cAIx, %  
 
 






ACE inhibitor + ARB 
 














2.03 ± 1.7 
 





8.3 ± 2.4 
 























7.3.1  Proteinuria 
Following 6 weeks’ dosing there was no change in proteinuria, as measured by 24-hour 
protein excretion or PCR, in the placebo or nifedipine arms. Sitaxsentan, however, 
significantly reduced proteinuria (Fig 7.2). The observed means ( SEM) for 24-hour 
proteinuria were 2.07  0.34 g/d at baseline and 1.46  0.26 g/d at 6 weeks (P < 0.0001). 




Figure 7.2 Effects of placebo, sitaxsentan and nifedipine on proteinuria 
(A) 24-hour proteinuria and (B) PCR. Values are given as mean % change from 
baseline  SEM at week 3 and week 6. * p < 0.001 for sitaxsentan vs. both 
placebo and nifedipine 
 
7.3.2 Mean 24-hour ambulatory blood pressure 
In the placebo phase there was no significant change in BP as measured by MAP, 
systolic and diastolic BP. Sitaxsentan significantly reduced all 3 parameters by ~ 4 mm 
Hg when compared to baseline, this effect was seen by week 3.  After 6 weeks of dosing 
there were no differences in reduction from baseline BP between sitaxsentan and 
nifedipine LA. Systolic BP was reduced by -3.6 ± 1.5 versus -4.9 ± 1.6 mm Hg, diastolic 
BP by -3.6 ± 1.0 versus -3.2 ± 1.0 mm Hg and MAP by -3.7 ± 1.0 versus -3.8 ± 1.1 mm 
Hg (mean ± SEM for sitaxsentan and nifedipine respectively). 
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7.3.3 Diurnal variation in systolic BP (SBP) 
At baseline, for all 3 phases of the study there was a nocturnal dip in SBP that did not 
differ between treatment arms:  placebo -5.2 ± 5.3%, sitaxsentan -5.4 ± 4.6%, nifedipine 
-5.7 ± 5.0% (ANOVA p = 0.88). Following 6 weeks’ treatment this nocturnal dip 
persisted in all 3 treatment arms: placebo -4.8 ± 7.3%, sitaxsentan -8.8 ± 5.9%, 
nifedipine -4.6 ± 4.9%. However, whereas placebo and nifedipine did not change the 
degree of nocturnal dip in SBP between baseline and week 6, the dip was greater 
following treatment with sitaxsentan (Figure 7.4), baseline vs. week 6: placebo -6.8 ± 
7.5 vs. -6.5 ± 9.8 mmHg, p = 0.88; sitaxsentan -7.0 ± 6.2 vs. -11.0 ± 7.8 mmHg, p < 
0.05; nifedipine -7.5 ± 6.9 vs. -6.0 ± 6.4 mmHg, p = 0.27.  
 
7.3.4 Diurnal variation in diastolic BP (DBP) 
As for SBP, there was a nocturnal dip in DBP at baseline that did not differ between 
treatment arms: placebo -7.6 ± 6.4%, sitaxsentan -7.4 ± 4.2%, nifedipine -8.3 ± 5.1% 
(ANOVA p = 0.73). Following 6 weeks’ treatment this nocturnal dip in DBP persisted in 
all 3 treatment arms: placebo -7.2 ± 5.7%, sitaxsentan -10.4 ± 5.9%, nifedipine -7.0 ± 
5.1%. However, similar to SBP, whereas placebo and nifedipine did not change the 
degree of nocturnal dip in DBP between baseline and week 6, sitaxsentan increased the 
dip (Figure 7.4), baseline vs. week 6: placebo -6.3 ± 5.6 vs. -6.0 ± 4.9 mmHg, p = 0.83; 
sitaxsentan -6.0 ± 3.6 vs. -8.3 ± 5.1 mmHg, p < 0.05; nifedipine -6.9 ± 4.4 vs. -5.7 ± 4.1 
mmHg, p = 0.08. 
 
7.3.5 Diurnal variation in pulse pressure (PP) 
There was no significant nocturnal dip in PP at baseline in the 3 phases of the study. 
Although this remained the case following 6 weeks of placebo and nifedipine, treatment 
with sitaxsentan was associated with the development of a nocturnal dip in PP, day vs. 
night: day vs. night: 46 ± 7 vs. 43 ± 7 mmHg, p < 0.01. 
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7.3.6 Arterial Stiffness 
Placebo had no significant effect on PWV or cAIx over the 6-week study period, 
whereas, sitaxsentan reduced both by study end. PWV fell by 4.8% compared to 
baseline a difference of ~ 9% when compared to placebo (P < 0.001 Figure 7.5) and 
cAIx fell by 5.3% compared to baseline a difference of ~5% when compared to placebo 
(P = 0.001). Although nifedipine caused a similar fall in PWV when compared to 
sitaxsentan (-0.4 ± 0.2 versus -0.4 ± 0.2 m/s; P >0.05), only sitaxsentan reduced cAIx 
after 6 weeks of dosing. 
 
7.3.7 Plasma ET-1 
Plasma ET-1 levels were unchanged throughout the study. In particular there was no 
change between baseline and 6 weeks of sitaxsentan therapy (3.6 ± 0.5 versus 3.7 ± 0.5 
pg / ml) 
 
7.3.8 Adverse events 
There were no significant differences in adverse events between the 3 groups (see table 
7.2). In particular, there was no evidence of significant fluid retention as measured by 






Figure 7.3 Effects of placebo, sitaxsentan and nifedipine LA 30mg on 
24h BP 
(A) mean arterial pressure, (B) systolic blood pressure, and (C) diastolic blood 








Figure 7.4 Nocturnal dip systolic and diastolic BP and pulse pressure   
Baseline and following 6 weeks’ treatment with placebo, sitaxsentan and 








SBP p = 0.79 p = 0.02 p = 0.28
 
DBP p =0.75 p = 0.03 p = 0.12
 








































































Figure 7.5 Effects of placebo, sitaxsentan and nifedipine LA 30mg on AS 
(A) pulse wave velocity, and (B) central augmentation index.  
For (A), * P < 0.01 and  + P < 0.05 for sitaxsentan and nifedipine vs. placebo. 









Table 7.2 Adverse events reported  
  
Placebo 
(n = 27) 
 
Sitaxsentan 
(n = 27) 
 
Nifedipine  































Discontinuation due to adverse  








Adverse events reported 
 >5%, n (%) 
    
   Headache 
 
   Nasal congestion 
 
   Flushing 
    
   Diarrhoea 
    
   Nausea & Vomiting 
    
   Back pain 
    






























































Previous studies have suggested that acute selective ETA antagonism lowers BP and 
proteinuria and improves renal blood flow132, 237. These beneficial changes in renal 
haemodynamics were abolished with concomitant ETB antagonism132. Furthermore these 
effects appear to be synergistic with RAAS blockade suggesting that ETA antagonism 
has a potential additional renoprotective role232, 238. Indeed, our department has shown 
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that proteinuria can be reduced by an additional ~30% with acute ETA antagonism in 
patients on maximal RAAS blockade238.  
 
This study has demonstrated that the acute effects of ETA antagonism on proteinuria BP 
and AS are sustained with chronic dosing of an oral ETA antagonist. Again, these effects 
were seen in patients already receiving optimal ACE-I/ARB therapy. This would suggest 
a possible role for ETA receptor antagonists in the treatment of proteinuric renal disease. 
 
Reduction of proteinuria is seen as important in both reducing the risk of CKD and 
associated CVD239. Current management of proteinuria revolves around good BP control 
and blockade of the RAAS. However, despite maximal therapy, many patients continue 
to have ongoing significant proteinuria240. The cohort of patients from this study, despite 
being on maximal tolerated RAAS blockade, had ongoing significant proteinuria at ~2 
g/d (range 0.3 to 7.8 g/d). The results of this study show that chronic ETA antagonism is 
a novel therapeutic approach for further reducing proteinuria.  
 
The effects of sitaxsentan on proteinuria in this study are, at least in part, independent of 
changes in systemic BP and are likely do to changes in renal haemodynamics (See 
chapter 6). Furthermore, despite nifedipine achieving similar BP effects to sitaxsentan, 
only sitaxsentan significantly reduced proteinuria. These findings are in keeping with a 
subsequent study using atrasentan (another selective ETA antagonist), which showed that 
chronic selective ETA antagonism in proteinuric kidney disease has additional beneficial 
effects on proteinuria when used in conjunction with RAAS blockade241.   
 
The current study confirms that ETA antagonism reduces BP in CKD. In the current 
study sitaxsentan caused a modest reduction in MAP (~4 mm Hg). It may be that this 
effect would have been more impressive had the subjects not had such good BP control. 
Previous studies in hypertensive patients suggest that chronic ETA antagonism is 
effective in reducing BP.138, 242 Furthermore the recent study by Andress et al. using 
atrasentan in diabetic nephropathy showed a mean fall in SBP of ~10 mmHg, though 
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these patients had much poorer BP control at baseline with a mean SBP of ~137 mm 
Hg241. 
 
In health, BP shows a diurnal variation with a nocturnal dip of ~10-20% (commonly 
known as a ‘dipping’ BP profile)243, 244. Non-dipping BP (often defined as a fall in 
nocturnal BP of <10%244) is associated with an increased risk of CVD, so BP dipping is 
thought to confer benefit.245 A few studies have examined the diurnal variation of BP in 
CKD246-248. They suggest that not only is non-dipping a feature of CKD but also, as GFR 
declines, reverse dipping (nighttime BP readings that are higher than those during the 
day) becomes more apparent. Importantly, loss of nocturnal dipping is associated with 
CKD progression249. 
 
The results of this study show that 6 weeks’ treatment with a selective ETA receptor 
antagonist increased the nocturnal dip in both SBP and DBP in patients with CKD. 
Sitaxsentan also allowed the development of a nighttime dip in pulse pressure. A higher 
24h ambulatory pulse pressure, along with a loss of nocturnal BP dip, has been shown to 
be independent predictors of nephropathy progression in patients with type 2 diabetes250. 
Furthermore, a high pulse pressure is associated with brain251 and kidney252 damage. AS 
is a major determinant of pulse pressure and it may be that the beneficial effects of 
sitaxsentan on PWV partly explain the effects on pulse pressure. 
 
Sitaxsentan has a significant effect on AS, as measured by PWV and cAIx, when 
compared to placebo in this study. These effects are most likely to be related to BP 
change rather than direct effects on endothelial function, supported by similar PWV 
results in the nifedipine arm of the study.  
 
There have been observations in previous studies of significant and occasionally life-
threatening fluid retention in subjects receiving ET antagonists253. The ASCEND study 
examining avosentan in diabetic nephropathy is the most notable, having to be 
terminated prematurely due to greater serious adverse cardiovascular events in the 
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avosentan groups, including a 3-fold increase in episodes of acute congestive heart 
failure254. It has been postulated that the cause of excess fluid retention could be 
secondary to ETB blockade, altering sodium and water homeostasis126. In the current 
study there was no observed weight gain, clinically significant oedema, or fall in 
haemoglobin or haematocrit. Interestingly, plasma ET-1 levels were unaltered 
throughout the study, which would suggest that there was no functional blockade of the 
ETB receptor (see also chapter 4) affecting ET-1 clearance. I have previously shown that 
this dose of sitaxsentan does not block ET-3 mediated endothelium-dependent 
vasodilatation, whereas bosentan does.  
 
In summary, the current study suggests that selective ETA antagonism is a novel 
therapeutic target in patients with CKD already on maximally tolerated RAAS blockade. 
Reduction of BP may depend on the initial level of BP, whereas effects on proteinuria 
appear to be BP-independent. Further larger trials are warranted to assess the efficacy 


















































The studies presented in this thesis have examined cardiovascular risk in CKD and how 
this risk may be modified by antagonism of the ETA receptor.  These studies support a 
potential clinical role for ET antagonists, particularly in patients with non-diabetic 
proteinuric CKD. 
 
Cardiovascular risk factors in a cohort with inflammatory renal disease  
The studies presented in chapter 3 and 4 provide further information regarding 
cardiovascular risk in patients with renal disease. I have shown in a cohort of patients 
with acute inflammatory renal disease that renal impairment is likely to have a 
significant impact on AS and a far greater impact than inflammation or classic CVD risk 
factors. Interestingly, however, once remission is achieved it is the classic CVD risk 
factors which become the most important predictors of AS and endothelial dysfunction. 
These observations would suggest that every effort should be made to achieve remission 
quickly to protect and preserve renal function in this cohort, and that BP and lipid 
management should form the basis of CVD primary prevention. 
 
Functional blockade of ET receptors  
The study presented in chapter 4 supports the theory that bosentan, but not sitaxsentan, 
causes functionally important blockade of the ETB receptor. Prior to this study, 
selectivity of ETRAs was based on in vitro competitive receptor assays with little known 
of the functional effects of these drugs in vivo, and particularly in the target species, 
man. This study has, for the first time, provided evidence that a highly selective (6,500-
fold ETA/ETB) ETA antagonist, namely sitaxsentan, does not cause functional ETB 
antagonism. This work is consistent with that of Maguire et al. showing, when moving 
from selectivity in cloned receptors to tissues, that selective inhibitors, like sitaxsentan, 
gain selectivity where as less selective agents, like bosentan, lose any selectivity they 




The method described here could be used to investigate the selectivity of other ETRAs. 
Indeed, the failure of previous trials such as the ASCEND254 trial may well in part be 
down to lack of ETA receptor specificity at the doses used.  A recent editorial in the 
Journal of the American Society of Nephrology also made the point that a good 
understanding of the pharmacodynamics of ETRAs remains elusive, particularly the 
mechanisms behind adverse events and suggest further research is required in this 
area256.  Specific knowledge of the in vivo selectivity of these drugs would significantly 
help achieve this goal, and would be a valuable addition to the clinical investigation of 
new ETA selective drugs.  
 
Acute and chronic ETA antagonism on renal and systemic haemodynamics 
The study presented in chapter 6 is the first study to examine the systemic and renal 
haemodynamic effects of an oral ETRA. It confirmed that ET-1 acting through the ETA 
receptor plays an important role in systemic and renal vascular tone in patients with 
CKD. Acute dosing of the oral ETA antagonist, sitaxsentan, caused a sustained drop in 
vascular resistance over the 4-hour study period. Within the kidney there was a 
reduction in EFF (~4%), but no change in renal blood flow. After 6 weeks, sitaxsentan 
was still exerting its systemic and renal effects. The significant reduction in GFR 
(9/ml/min) over the 6-week study period would be in keeping with reduced efferent 
arteriolar tone with subsequent fall in glomerular pressures and filtration rate, an effect 
similar to RAAS blockade and one which is thought to be renoprotective257. 
Interestingly, as these patients were already receiving maximal tolerated RAAS 
blockade these effects on renal haemodynamics are of more interest and suggest that 
ETRAs could be used in conjunction with RAAS blockade to reduced glomerular 
pressure and in turn slow renal progression. 
 
Importantly, despite a fall in BP, vascular resistance and GFR over the 6-week dosing 
period there was no evidence of impaired salt handling by the kidney, suggesting that 
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there was no significant ETB receptor blockade and that, at least in this relatively healthy 
group of CKD patients, complications secondary to salt and water retention are unlikely.    
 
Effect of chronic ETA antagonism on markers of renal and cardiovascular 
disease progression 
The study described in chapter 6 suggests that selective ETA antagonism may have a 
potential therapeutic role in slowing renal disease progression and reducing 
cardiovascular risk, namely through a reduction in BP and proteinuria.  
 
Hypertension is common in the CKD population and is associated with an increased risk 
in cardiovascular disease and renal disease progression. Conversely, reducing BP 
reduces cardiovascular mortality258 and slows the rate in decline of eGFR35,  particularly 
in patients with proteinuric CKD. Unfortunately, though hypertension can be difficult to 
treat in this population and despite treatment with multiple antihypertensive agents the 
majority of CKD patients fail to reach target BP259. Proteinuria is a common feature of 
CKD and its presence is independently associated with an adverse renal outcome39. 
Current management revolves around BP reduction, primarily via blockade of the RAAS 
with either ACE-I or ARB260. Unfortunately, however, many CKD patients have 
significant residual proteinuria despite optimal treatment261. The study in chapter 7 
showed that ETA antagonism can further lower BP and proteinuria in this population and 
that this effect is sustained over a 6-week period. These findings were in keeping with 
those of Chapter 6 and suggest that one of the major benefits of this treatment is its 
direct effect on glomerular pressures.  More importantly, these effects were observed in 
a group of patients who were already receiving maximal therapy with an ACE-I and/or 
ARB and had reasonable BP control. This would suggest that ETRA therapy could offer 
a novel approach to improve BP and proteinuria in CKD patients, which, in theory, may 
slow renal disease progression and reduce cardiovascular risk.  
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Safety of chronic ETA antagonism in the CKD population 
The safety of ETRAs remains of paramount concern, particularly the risk of salt and 
water retention, which has been observed with mixed and “selective” ETRAs262-264.  
Indeed, fluid retention has led to the premature termination of clinical trials and has been 
blamed, in large part, for the neutral/negative results in heart failure studies265.  In the 
studies described within this thesis, there was no evidence of fluid retention as measured 
by weight gain or drop in haematocrit, with the treatment being well tolerated by all 
participants. It may be that previous issues relating to fluid retention are due to blockade 
of the ETB receptor and would explain why it was not observed in the studies described 
here. Importantly though, to date sitaxsentan is the only ETRA that has been shown to 
have no functional effects on the ETB receptor (see chapter 5). However, ours were 
small studies, not in diabetic nephropathy, and in patients selected to avoid associated 
CVD, so it may be unsafe to extrapolate too far.  
 
In our cohort of patients we saw no abnormalities of liver function with sitaxsentan. 
However, shortly after the competition of these studies it became clear that there was a 
small but significant risk of liver failure. In total, 7 patients with severe liver toxicity 
have been described, of whom 2 died, 1 underwent heart/liver/lung transplant and the 
others fully recovered with drug withdrawal and steroids266.  Sulphonamide ETRAs are 
known to cause liver impairment, which appears to be direct, and dose-dependent 
toxicity. There is some evidence this may be due to drug-induced impairment of a bile 
salt transporter267. With bosentan, withdrawal of the drug leads, in most cases, to 
complete normalisation of liver function within a few weeks. Similar cases have been 
seen with sitaxsentan. However, the 7 severe cases appear different. Following 
withdrawal of the drug, liver function continued to decline. The histological pattern 
(presence of lymphocytes and eosinophils) and the clinical course suggested an 
idiosyncratic mechanism.  Furthermore, no reports of death secondary to liver failure 
have been reported with bosentan (>80,000 patients treated) or ambrisentan (>10,000 
patients treated) compared to two deaths in ~2000 patients treated with sitaxsentan. In 
view of these finding sitaxsentan was voluntarily withdrawn from the global market in 
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The observations in this thesis raise further questions to be answered and areas to 
explore. Some of these are discussed below: 
 
1. Arterial stiffness and endothelial function in acute kidney injury 
Based on the finding of chapter 3 and 4 it would be of great interest to further investigate 
markers of arterial stiffness and endothelial function in other cohorts of patients with 
acute kidney injury. In particular, comparing a cohort with a non-inflammatory cause, 
such as urinary obstruction, with the current cohort would help to confirm or refute the 
finding that renal function is the main determinant of AS in acute kidney injury. 
 
2. Examination of functional ETB blockade produced by other ETRAs 
Following on from the study described in chapter 5 it would be interesting to further 
investigate the degree of ETB blockade produced with other ETRAs particularly 
following the voluntary withdrawal of sitaxsentan. Theoretically, truly selective ETA 
antagonism should confer benefits in terms of natriuresis, diuresis, and glomerular 
haemodynamics. However, to date there is no evidence to suggest the selective ETA 
antagonists such as ambrisentan, atrosentan and zibotentan truly are functionally 
selective at their current doses, and good reasons to think they are not268. Important 
questions regarding efficacy and safety remain with this class of drug, and functional in 
vivo receptor studies would be of great benefit. The study described in chapter 4 is a 
simple and novel method for testing functional receptor antagonism in man using well 
described and tested techniques and could easily be applied to investigate other ETRAs. 
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3. Examination of the effects of ETRAs on sodium homeostasis 
Peripheral oedema is one of the most common and troublesome adverse events seen with 
both mixed and selective ETRAs138, 146, 242. This adverse effect has had significant 
clinical consequences leading to the failure of many trials262, 263. Antagonism of the ETB 
receptor with mixed antagonists may be contributing to fluid retention through inhibition 
of natriuresis and diuresis. The marginal selectivity of some “selective” ETA antagonists 
may mean that at high doses they also cause functional ETB blockade. However, there is 
also some evidence that ETA receptors within the collecting ducts may also contribute to 
natriuresis and diuresis126. Further studies are therefore required to define how these 
ETRAs exert their effects on sodium homeostasis.  
 
4. Selective ETA antagonism in proteinuric CKD 
Based on the results of studies 6 and 7 and the more recently published data regarding 
atrasentan, a highly selective ETA antagonist, in diabetic nephropathy, ETA antagonists 
appear to confer additional renal and cardiovascular protection via reductions in 
proteinuria and BP in CKD patients264, 269. Further research is therefore warranted in this 
area.  A large phase III trial examining atrasentan in diabetic nephropathy is currently 
underway. This study, which started in May 2013, aims to enrol 4148 patients with 
diabetic nephropathy, randomising them to atrasentan or placebo. Treatment will 
continue for 48 months with the primary endpoints being time to doubling of serum 
creatinine or onset of end stage renal disease. The study is due to complete in March 
2017 and will be the first large scale trial of endothelin antagonism in CKD 
(ClinicalTrials.gov NCT01858532). 
 
5. Mixed vs. Selective ETRAs in proteinuric CKD 
Both selective ETA and mixed ETA/B receptor antagonists are now available for clinical 
use. However, there remain few comparative studies of their effects in CKD. It would be 
of great interest to see if the results seen in Chapter 6 & 7 (proteinuria, BP and AS 
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reduction) are similar with a mixed ETA/B blocking strategy. In particular, whether or not 
the side effect profile is as favourable given the theoretical risk of blocking ETB receptor 
mediated natriuresis and so potentially risking fluid retention with a mixed approach. 
 
In acute studies in subjects with CKD, the renal vasodilatation seen with selective ETA 
receptor antagonism is attenuated with additional ETB receptor blockade270, suggesting 
that tonic ETB receptor-mediated renal vasodilatation plays a key role in opposing renal 
vasoconstriction. This is likely to be of particular importance in CKD, where baseline 
renal vascular resistance is high. Conversely, proteinuria reduction is seen with both 
approaches237, 271. Although both approaches may be of benefit in CKD, there are no 
head-to-head studies with chronic dosing.  
 
6. Management of scleroderma kidney 
Scleroderma renal crisis (SRC) is an important complication of scleroderma associated 
with significant morbidity and mortality. Current treatment of patients with SRC focuses 
on RAAS blockade, ideally using ACE-I. ET-1 is implicated in the development of 
scleroderma with patients showing increased plasma and tissue concentrations of ET-
1272, 273. A trial of the mixed receptor antagonist bosentan in 122 patients with 
scleroderma showed a 48% decrease in mean number of new digital ulcers during the 
16-week treatment period144. Currently, data regarding the use of ETRAs in patients 
with scleroderma are limited, with the majority of studies focusing on pulmonary arterial 
hypertension113. I, in conjunction with other renal colleagues, have described a case 
study using sitaxsentan in the treatment of scleroderma kidney274. In this case the patient 
was already established on maximal tolerable RAAS-blocking treatment. Introduction of 
a selective endothelin-A receptor antagonist followed by a direct renin inhibitor 
provided excellent BP control and complete abrogation of heavy proteinuria. This was 
associated with a decrease in kidney function, with serum creatinine level increasing by 
around 30% before stabilizing. Whether this would protect residual renal function in the 
longer term remains unclear. Our observational case study suggests that ETRAs may 
offer therapeutic benefits in patients with SRC on top of standard treatment and warrants 
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